WO2008000020A1 - Improved process - Google Patents

Improved process Download PDF

Info

Publication number
WO2008000020A1
WO2008000020A1 PCT/AU2007/000879 AU2007000879W WO2008000020A1 WO 2008000020 A1 WO2008000020 A1 WO 2008000020A1 AU 2007000879 W AU2007000879 W AU 2007000879W WO 2008000020 A1 WO2008000020 A1 WO 2008000020A1
Authority
WO
WIPO (PCT)
Prior art keywords
keratin
keratin sample
abnormal component
data
detecting
Prior art date
Application number
PCT/AU2007/000879
Other languages
French (fr)
Inventor
Gary L. Corino
Original Assignee
Fermiscan Australia Pty Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006903508A external-priority patent/AU2006903508A0/en
Priority to AT07719118T priority Critical patent/ATE520345T1/en
Priority to AU2007264394A priority patent/AU2007264394B2/en
Priority to BRPI0713885-7A priority patent/BRPI0713885A2/en
Priority to ES07719118T priority patent/ES2371368T3/en
Priority to CA002652955A priority patent/CA2652955A1/en
Application filed by Fermiscan Australia Pty Limited filed Critical Fermiscan Australia Pty Limited
Priority to EP07719118A priority patent/EP2032031B1/en
Priority to KR1020097001887A priority patent/KR101087576B1/en
Priority to US12/306,134 priority patent/US20090325303A1/en
Priority to CNA2007800243800A priority patent/CN101478916A/en
Priority to JP2009516820A priority patent/JP2009541747A/en
Publication of WO2008000020A1 publication Critical patent/WO2008000020A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/07—Endoradiosondes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Definitions

  • a method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological -state comprising the steps of exposing the keratin sample to a swelling substance so as to penetrate the keratin sample thereby producing a derived chemical substance; obtaining data from the derived chemical substance; comparing the data obtained from the derived chemical substance with a second group of data contained in a reference database so as to identify the presence of the abnormal component in the keratin sample; whereby detection of the abnormal component is consistent with a presence of the pathological state in the subject.
  • X-ray diffraction analysis has shown that subjects with a plurality of certain types of cancers (colon, breast and prostate) and other pathological states (Alzheimer's disease) produce hair samples that have abnormalities in them.
  • the abnormalities are detectable using X-ray diffraction techniques and are consistent with the presence of the pathological state itself.
  • X-ray diffraction techniques can identify the presence of an abnormality in hair or other keratin samples, X-ray diffraction techniques are limited in that they do not reveal the nature of the abnormal component (i.e. whether the abnormality represents an inclusion of a chemical substance not normally present or rather a defect in the structure of a keratin fibril for example in the hair) .
  • a structural abnormality therefore can have the same proportion of chemical molecules present but differ structurally in geometric orientation of the molecules or their chemical bonding. Therefore, the pathological state can lead to structural changes in chemical bonding in the hair even though the chemical molecules forming the hair are in the same proportion as occurs in normal hair.
  • the pathological state can be identified with greater specificity and sensitivity. Identification of the abnormal component means that additional information is then provided about the nature of the pathological state.
  • a problem sought to be solved by the present invention is the ability to chemically penetrate a hair sample so as to detect an abnormal component within the hair sample taken from a subject with a pathological state.
  • a method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological state comprising the steps of:
  • the swelling substance includes formic acid.
  • the second group of data is correlated with the presence of the pathological state in the subject.
  • the second group of data is causatively associated with the presence of the pathological state in the subject.
  • the swelling substance is selected from a plurality of different swelling substances .
  • the keratin sample is selected from a plurality of different keratin samples .
  • the second group of data is selected from a plurality of different groups of data.
  • the derived data and the second group of data are analyzed using a plurality of different methods of comparison .
  • the keratin sample can be obtained and analyzed in association with at least one of a pharmacy, a test kit, the subject's home, a health care clinic and a testing laboratory or any convenient location (office, field or barn) .
  • the subject is selected from the group consisting of a human, and an animal.
  • Figure 1 shows the application of a swelling substance to a keratin sample for use in diagnostic testing.
  • Figure 2 shows a plurality of different chemical substances being applied in the alternative to a keratin sample.
  • Figure 3 shows a plurality of different keratin samples taken from different subjects with different pathological states (or the same subject with several pathological states) or from a plurality of different mammalian species.
  • Figure 4 shows a plurality of different methods of analysis being used to analyze data produced according to the first embodiment disclosed in Figure 1.
  • Figure 5 shows the method of analyzing a keratin sample being implemented in use, wherein a sample can be collected from a subject at a health care clinic, a collecting room or using a kit at a convenient location to rhe subject (home, field, barn, etc) .
  • Figure 6 illustrates results of SAXS analysis applied to samples treated in accordance with embodiments of the method of the present invention.
  • An “animal” is defined as a living organism characterized by the capacity for voluntary motion, sensation and the ingestion of food such as plants and other animals, and which has a non-cellulose cell wall.
  • the plurality of different selections and forms pertaining to the invention as claimed include ⁇ .he selections and forms as appearing in the body of the specification.
  • “Mammalian species” includes the types of species as appearing in the body of the specification. It can include a human, a pet such as a dog or cat or a variety of other animals with hair.
  • a "keratin sample” or “keratin substance” is a sample that is substantially comprised of keratin.
  • the keratin substance 16 can include human scalp or body hair and in particular pubic hair, pet hair, animal hair or hair from a member of a mammalian species in general, or other keratin based materials such as nail clippings or an eyelash.
  • a "subject” can include a mammalian species.
  • a mammalian species can include a human, a pet such as a dog or cat or a variety of other animals.
  • Figure 1 illustrates a method of analyzing a keratin sample 16.
  • Figure 1 shows a first container 12 which holds a swelling substance 14.
  • a keratin sample 16 is taken from subject 11, wherein the subject 11 can include a mammalian species.
  • a mammalian species can include a human, a pet such as a dog or cat or a variety of other animals.
  • the keratin substance 16 can include human scalp or body hair and in particular pubic hair, pet hair, animal hair or hair from a mammalian species in general, or other keratin based materials such as nail clippings or an eyelash.
  • the keratin sample 16 is exposed to the swelling substance 14.
  • a derived chemical substance 18 is obtained from application of the swelling substance 14 to the keratin sample 16 whereby the swelling substance 14 penetrates the keratin sample 16.
  • the derived chemical substance 18 is collected in the second container 19 (alternatively and without loss of generality only one container need be used) .
  • the derived chemical substance 18 located in the second container 19 is then taken to a laboratory 20 at the place of application of the swelling substance 14.
  • the laboratory 20 will then use a plurality of diagnostic tests to obtain data 22 which can be compared with data 24 located in a reference database 25 so as to determine if the subject 11 has a pathological state.
  • the reference database 25 can be obtained from a plurality of control samples taken from normal subjects and subjects with a plurality of different pathological states.
  • the data 22 can be compared with dara 24 in the reference database 25 to determine whether or not the subject 11 has a pathological state, for example if the reference database 25 indicates that the result in question is both correlated and causatively linked to a pathological state then a meaningful comparison can be considered. Additionally zero correlation or no information being provided in rhe case of no association with an abnormal component being present 1 in the derived chemical substance 18 can in certain instances be consistent with an abnormality being a defect in protein folding, that is a structural defect in the keratin sample 16 as opposed to an additional inclusion of a component that may or may not be ordinarily found in the keratin sample 16 such as a metal or other compound (whereby no inclusion is washed out into the derived chemical substance 18) .
  • Figure 2 shows an embodiment of the present invention in which the sensitivity or specificity of the method described in Figure 1 is improved by way of changing the swelling substance 14.
  • Figure 2 shows a plurality of different swelling substances 14, being Sl, S2...SN.
  • the data 22, not shown, is analyzed by comparing the data 22 with the data 24 (from a reference database 25 as seen in Figure 1) so as to select a swelling substance from the set Sl... SN, which is adapted to remove the defect in the keratin sample 16 by either altering the structural nature of the keratin sample 16 so as to restore normal folding and configuration of the keratin sample 16 or by transferring, by way of application of the swelling substance 14 to the keratin sample 16, the component causing the abnormality in the keratin sample 16 to the derived chemical substance 18 (this can involve for example formic acid penetrating and washing out an inclusion from a hair sample) .
  • Dithio-Threitol or DTE (Dithioerythritol) and urea or other protein denaturing agents.
  • DTE Dithioerythritol
  • urea or other protein denaturing agents urea or other protein denaturing agents.
  • formic acid other considerations are relevant such as toxicity and in the case of reducing agents the fact that the structure of the keratin sample 16 can be substantially destroyed by the application of the reducing agent.
  • a swelling substance 14 which may not destroy the structure of a keratin sample 16 after application.
  • Figure 3 shows the use of a specific swelling substance 14, for a given mode of operation in -association with a plurality of different keratin samples 16 to yield a derived chemical substance 18.
  • the plurality of different keratin samples 16 can be taken from a plurality of different mammalian species. Alternatively or additionally, the plurality of different keratin samples 16 can be taken from subjects 11 who are suspected to have a plurality of different pathological states .
  • the variations in swelling substances as disclosed in Figure 2 and the variations in keratin samples 16 as disclosed in Figure 3 can be used to identify a particular capability in a particular swelling substance 14 or a particular susceptibility in a given keratin sample 16. For example if a given swelling substance 14 such as formic acid was known to remove an abnormal component from a keratin sample 16 during a particular concentration range and a particular sub-range of the concentration was shown to yield a significantly improved result then a new availability in the formic acid could exist.
  • a given swelling substance 14 such as formic acid was known to remove an abnormal component from a keratin sample 16 during a particular concentration range and a particular sub-range of the concentration was shown to yield a significantly improved result then a new availability in the formic acid could exist.
  • a particular susceptibility will occur if a keratin sample 16 is known to yield a conclusive result in association with a given mode of operation and a given swelling substance 14 that leads to an improvement in specificity or sensitivity of a diagnostic test to look for the presence of the abnormal component.
  • Figure 3 can include a keratin sample 16 taken from a subject 11 who is suspected of having a pathological state which can include one or more cancers or pathological states such as lung cancer, Creutzfeldt-Jacob disease, mad cow disease, infection (bacterial, viral, or a Prion or more generally by other agents), a metabolic disorder (which can include diabetes) , or alternatively hepatitis, heart disease or liver dysfunction.
  • a pathological state which can include one or more cancers or pathological states such as lung cancer, Creutzfeldt-Jacob disease, mad cow disease, infection (bacterial, viral, or a Prion or more generally by other agents), a metabolic disorder (which can include diabetes) , or alternatively hepatitis, heart disease or liver dysfunction.
  • the keratin sample 16 can include Keratin Type I and Keratin Type II.
  • Figure 4 shows an embodiment of the method for detecting the presence of a pathological state in which a given swelling substance 14 and a given keratin sample 16 are used in association with a plurality of different types of methods of comparison between the data 22 and a second group of data 24 contained in the reference database 25 so as to produce an improvement in specificity or sensitivity of the method of analyzing the keratin sample 16.
  • An advantage of the present embodiment is that if the abnormal component is present in the derived chemical substance 18 then the derived chemical substance 18 can be further analyzed for the purpose of identifying the nature of the abnormal component so as to provide a health care practitioner with more information about the pathological state. If the abnormal component is a trace metal then atomic absorption spectroscopy or ICP-mass spectrometry could be applied to the derived chemical substance 18 to confirm the nature of the abnormal component.
  • the abnormal component in the derived chemical substance 18 is a protein, a carbohydrate, a fatty acid or more generally of organic origin and an antibody can be raised against the abnormal component then a plurality of different techniques such as Western blot analysis, ELISA or cell agglutination assays can be used in an attempt to characterize the abnormal component. In certain instances, immuno-electron microscopy can be used in an attempt to identify the abnormal component in the keratin sample 16 without the need for the use of the derived chemical substance 18 to subsequently be obtained. If the abnormal component is associated with genetic material (being hereditary in narure or acquired by way of a viral vector) then an amplification technique could be applied to determine the sequence and conformation of the abnormal component . In use
  • Figure 5 shows an embodiment of the present invention in use.
  • a keratin sample 16 can be collected from a subject at a pharmacy 26 .
  • the keratin sample 16 can then be sent to a testing laboratory 34 so as to perform the method for detecting the presence of an abnormal component in the keratin sample 16 as seen in Figure 1.
  • test kit 28 can be obtained so as to use the test kit 28 embodying the method of detection at the subject's home 30, in association with consultation of the subject's health care practitioner located at a health care clinic 32.
  • the subject 11 can visit his or her health care clinic 32 so as to provide the keratin sample 16.
  • the health care clinic 32 can perform the method of analyzing the keratin sample 16 themselves or in a further, preferred embodiment. ⁇ .he health care clinic 32 can obtain the keratin sample 16 from the subject 11 so as to forward the keratin sample 16 to the testing laboratory 34.
  • This methodology was applied to several hair fibers from individuals of known pathology to determine if the ring observed by Synchrotron Small Angle X-Ray Scatter (SAXS) of hair, specific for the presence of breast cancer, could be removed by such treatment.
  • Hair fibers from subjects with breast cancer were immersed in an 85% (v/v) solution of formic acid or in glacial acetic acid for 3 minutes at room temperature. The acid was then decanted and replaced with several changes of Milli-Q water. The fibers were allowed to dry then mounted into a sample holder for exposure to an X-ray source. SAXS image data was collected for these hairs .
  • Hair fibers that were taken from the same individual and subsequently treated with formic and acetic acid showed either significant reduction or complete removal of the ring in the zone of interest in the SAXS image.
  • Figure 6A is a SAXS image of a hair from an individual with breast cancer.
  • Figures 6B and 6C are SAXS images of hair fibers from the same individual post treatment with acetic acid and formic acid respectively. It can be seen from these images that the ring in the zone of interest is significantly diminished after treatment with either acid and hence such treatments may be used as a tool to investigate the underlying change in the fiber associated with the presence of breast cancer.

Abstract

A method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological state comprising the steps of : a) exposing the keratin sample to a swelling substance so as to penetrate the keratin sample thereby producing a derived chemical substance; b) obtaining data from the derived chemical substance; c) comparing the data obtained from the derived chemical substance with a second group of data contained in a reference database so as to identify the presence of the abnormal component in the keratin sample; whereby detection of the abnormal component is consistent with a presence of the pathological state in the subject.

Description

Improved Process
A method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological -state comprising the steps of exposing the keratin sample to a swelling substance so as to penetrate the keratin sample thereby producing a derived chemical substance; obtaining data from the derived chemical substance; comparing the data obtained from the derived chemical substance with a second group of data contained in a reference database so as to identify the presence of the abnormal component in the keratin sample; whereby detection of the abnormal component is consistent with a presence of the pathological state in the subject.
BACKGROUND
A variety of research to date has indicated the presence of abnormal changes in components of keratin samples, such as hair, taken from subjects, who are afflicted with a pathological state which can include cancer.
X-ray diffraction analysis has shown that subjects with a plurality of certain types of cancers (colon, breast and prostate) and other pathological states (Alzheimer's disease) produce hair samples that have abnormalities in them. The abnormalities are detectable using X-ray diffraction techniques and are consistent with the presence of the pathological state itself.
Whilst X-ray diffraction techniques can identify the presence of an abnormality in hair or other keratin samples, X-ray diffraction techniques are limited in that they do not reveal the nature of the abnormal component (i.e. whether the abnormality represents an inclusion of a chemical substance not normally present or rather a defect in the structure of a keratin fibril for example in the hair) . A structural abnormality therefore can have the same proportion of chemical molecules present but differ structurally in geometric orientation of the molecules or their chemical bonding. Therefore, the pathological state can lead to structural changes in chemical bonding in the hair even though the chemical molecules forming the hair are in the same proportion as occurs in normal hair.
A variety of different causes as to the nature of chemical abnormalities present in the hair of persons with a pathological state have been conjectured. It has been suggested that an increase in specific metals normally found in hair may be associated with various pathological states. Some researchers have conjectured that different types of growth factors can be found in increased proportions in the hair of cancer patients . Other researchers have suggested that rather than specific additions to normal hair such as increases in the content of certain metals present, that abnormal structures, for example a truncated form of keratin, can be present in hair taken from persons with certain pathological states such as breast cancer.
Irrespective of the truth of the above conjectures the structure of hair, contains a tightly bound cuticle surrounding a dense cortex so that it is often extremely difficult to chemically penetrate hair in an attempt to identify the presence of an abnormal component.
If the abnormal component whether structural or an atypical inclusion in hair taken from a subject with a pathological state, can be isolated, then the pathological state can be identified with greater specificity and sensitivity. Identification of the abnormal component means that additional information is then provided about the nature of the pathological state.
It is therefore seen that a problem sought to be solved by the present invention is the ability to chemically penetrate a hair sample so as to detect an abnormal component within the hair sample taken from a subject with a pathological state.
It is an object of the present invention to address or at least ameliorate some of the above disadvantages.
Notes
1. The term "comprising" (and grammatical variations thereof) is used in this specification in the inclusive sense of "having" or "including", and not in the exclusive sense of "consisting only of".
2. The above discussion of the prior art in the Background of the invention, is not an admission that any information discussed therein is citable prior art or parr of the common general knowledge of persons skilled in the art in any country.
BRIEF DESCRIPTION OF INVENTION
In one broad form of the invention there is provided a method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological state comprising the steps of:
a) exposing the keratin sample to a swelling substance so as to penetrate the keratin sample thereby producing a derived chemical substance;
b) obtaining data from the derived chemical substance;
c) comparing the data obtained from the derived chemical substance with a second group of data contained in a reference database so as to identify the presence of the abnormal component in the keratin sample;
whereby detection of the abnormal component is consistent with a presence of the pathological state in the subject.
Preferably, the swelling substance includes formic acid.
Preferably, the second group of data is correlated with the presence of the pathological state in the subject. Preferably, the second group of data is causatively associated with the presence of the pathological state in the subject.
Preferably, the swelling substance is selected from a plurality of different swelling substances .
Preferably, the keratin sample is selected from a plurality of different keratin samples .
Preferably, the second group of data is selected from a plurality of different groups of data.
Preferably, the derived data and the second group of data are analyzed using a plurality of different methods of comparison .
Preferably, in use, the keratin sample can be obtained and analyzed in association with at least one of a pharmacy, a test kit, the subject's home, a health care clinic and a testing laboratory or any convenient location (office, field or barn) .
Preferably, the subject is selected from the group consisting of a human, and an animal. BRIEF DESCRIPTION OF DRAWINGS
Figure 1 shows the application of a swelling substance to a keratin sample for use in diagnostic testing.
Figure 2 shows a plurality of different chemical substances being applied in the alternative to a keratin sample.
Figure 3 shows a plurality of different keratin samples taken from different subjects with different pathological states (or the same subject with several pathological states) or from a plurality of different mammalian species.
Figure 4 shows a plurality of different methods of analysis being used to analyze data produced according to the first embodiment disclosed in Figure 1.
Figure 5 shows the method of analyzing a keratin sample being implemented in use, wherein a sample can be collected from a subject at a health care clinic, a collecting room or using a kit at a convenient location to rhe subject (home, field, barn, etc) .
Figure 6 illustrates results of SAXS analysis applied to samples treated in accordance with embodiments of the method of the present invention. DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Embodiments of the present invention will now be described with reference to the accompanying drawings wherein:
Definitions:
An "animal" is defined as a living organism characterized by the capacity for voluntary motion, sensation and the ingestion of food such as plants and other animals, and which has a non-cellulose cell wall.
The plurality of different selections and forms pertaining to the invention as claimed include τ.he selections and forms as appearing in the body of the specification. "Mammalian species" includes the types of species as appearing in the body of the specification. It can include a human, a pet such as a dog or cat or a variety of other animals with hair.
A "keratin sample" or "keratin substance" is a sample that is substantially comprised of keratin. The keratin substance 16 can include human scalp or body hair and in particular pubic hair, pet hair, animal hair or hair from a member of a mammalian species in general, or other keratin based materials such as nail clippings or an eyelash. A "subject" can include a mammalian species. A mammalian species can include a human, a pet such as a dog or cat or a variety of other animals.
Unless otherwise indicated by the context, a claim to one element is consistent with a claim to at least one element. Figure 1 illustrates a method of analyzing a keratin sample 16. Figure 1 shows a first container 12 which holds a swelling substance 14. A keratin sample 16 is taken from subject 11, wherein the subject 11 can include a mammalian species. A mammalian species can include a human, a pet such as a dog or cat or a variety of other animals. The keratin substance 16 can include human scalp or body hair and in particular pubic hair, pet hair, animal hair or hair from a mammalian species in general, or other keratin based materials such as nail clippings or an eyelash.
The keratin sample 16 is exposed to the swelling substance 14. A derived chemical substance 18 is obtained from application of the swelling substance 14 to the keratin sample 16 whereby the swelling substance 14 penetrates the keratin sample 16. The derived chemical substance 18 is collected in the second container 19 (alternatively and without loss of generality only one container need be used) . The derived chemical substance 18 located in the second container 19 is then taken to a laboratory 20 at the place of application of the swelling substance 14. The laboratory 20 will then use a plurality of diagnostic tests to obtain data 22 which can be compared with data 24 located in a reference database 25 so as to determine if the subject 11 has a pathological state. The reference database 25 can be obtained from a plurality of control samples taken from normal subjects and subjects with a plurality of different pathological states.
The data 22 can be compared with dara 24 in the reference database 25 to determine whether or not the subject 11 has a pathological state, for example if the reference database 25 indicates that the result in question is both correlated and causatively linked to a pathological state then a meaningful comparison can be considered. Additionally zero correlation or no information being provided in rhe case of no association with an abnormal component being present1 in the derived chemical substance 18 can in certain instances be consistent with an abnormality being a defect in protein folding, that is a structural defect in the keratin sample 16 as opposed to an additional inclusion of a component that may or may not be ordinarily found in the keratin sample 16 such as a metal or other compound (whereby no inclusion is washed out into the derived chemical substance 18) .
Figure 2 shows an embodiment of the present invention in which the sensitivity or specificity of the method described in Figure 1 is improved by way of changing the swelling substance 14. Figure 2 shows a plurality of different swelling substances 14, being Sl, S2...SN.
In Figure 2 the data 22, not shown, is analyzed by comparing the data 22 with the data 24 (from a reference database 25 as seen in Figure 1) so as to select a swelling substance from the set Sl... SN, which is adapted to remove the defect in the keratin sample 16 by either altering the structural nature of the keratin sample 16 so as to restore normal folding and configuration of the keratin sample 16 or by transferring, by way of application of the swelling substance 14 to the keratin sample 16, the component causing the abnormality in the keratin sample 16 to the derived chemical substance 18 (this can involve for example formic acid penetrating and washing out an inclusion from a hair sample) . Whilst formic acid has been disclosed herein a number of other substances are amenable to penetrate a keratin substance so as to remove an abnormal component; other substances include acetic acid, propionic acid, butyric acid, trifluoracetic acid, monochloracetic acid, hydrochloric acid, dimethyl formamide, potassium iodide, sodium bromide, lithium bromide, lithium chloride, DTT
(Dithio-Threitol) or DTE (Dithioerythritol) and urea or other protein denaturing agents. However, unlike formic acid other considerations are relevant such as toxicity and in the case of reducing agents the fact that the structure of the keratin sample 16 can be substantially destroyed by the application of the reducing agent. In contrast formic acid is a swelling substance 14 which may not destroy the structure of a keratin sample 16 after application.
Figure 3 shows the use of a specific swelling substance 14, for a given mode of operation in -association with a plurality of different keratin samples 16 to yield a derived chemical substance 18. The plurality of different keratin samples 16 can be taken from a plurality of different mammalian species. Alternatively or additionally, the plurality of different keratin samples 16 can be taken from subjects 11 who are suspected to have a plurality of different pathological states .
The variations in swelling substances as disclosed in Figure 2 and the variations in keratin samples 16 as disclosed in Figure 3 (two are shown but more can be envisaged) can be used to identify a particular capability in a particular swelling substance 14 or a particular susceptibility in a given keratin sample 16. For example if a given swelling substance 14 such as formic acid was known to remove an abnormal component from a keratin sample 16 during a particular concentration range and a particular sub-range of the concentration was shown to yield a significantly improved result then a new availability in the formic acid could exist.
Similarly, as seen in Figure 3, for a given swelling substance 14, having a particular concentration, a systematic variation in the types of keratin samples 16 could disclose a susceptibility of a particular type of keratin sample 16 to a swelling substance 14 such as formic acid.
A particular susceptibility will occur if a keratin sample 16 is known to yield a conclusive result in association with a given mode of operation and a given swelling substance 14 that leads to an improvement in specificity or sensitivity of a diagnostic test to look for the presence of the abnormal component.
The plurality of different keratin samples 16, shown in
Figure 3 can include a keratin sample 16 taken from a subject 11 who is suspected of having a pathological state which can include one or more cancers or pathological states such as lung cancer, Creutzfeldt-Jacob disease, mad cow disease, infection (bacterial, viral, or a Prion or more generally by other agents), a metabolic disorder (which can include diabetes) , or alternatively hepatitis, heart disease or liver dysfunction. Further, without limitation the keratin sample 16 can include Keratin Type I and Keratin Type II.
Figure 4 shows an embodiment of the method for detecting the presence of a pathological state in which a given swelling substance 14 and a given keratin sample 16 are used in association with a plurality of different types of methods of comparison between the data 22 and a second group of data 24 contained in the reference database 25 so as to produce an improvement in specificity or sensitivity of the method of analyzing the keratin sample 16. The plurality of different comparison's 23 shown in Figure 4
(two are shown but more can be envisaged) can without limitation include variations in the mode of operation of the method of analyzing a keratin sample including spectral analysis or the use of pattern recognition computer programs .
An advantage of the present embodiment is that if the abnormal component is present in the derived chemical substance 18 then the derived chemical substance 18 can be further analyzed for the purpose of identifying the nature of the abnormal component so as to provide a health care practitioner with more information about the pathological state. If the abnormal component is a trace metal then atomic absorption spectroscopy or ICP-mass spectrometry could be applied to the derived chemical substance 18 to confirm the nature of the abnormal component. If the abnormal component in the derived chemical substance 18 is a protein, a carbohydrate, a fatty acid or more generally of organic origin and an antibody can be raised against the abnormal component then a plurality of different techniques such as Western blot analysis, ELISA or cell agglutination assays can be used in an attempt to characterize the abnormal component. In certain instances, immuno-electron microscopy can be used in an attempt to identify the abnormal component in the keratin sample 16 without the need for the use of the derived chemical substance 18 to subsequently be obtained. If the abnormal component is associated with genetic material (being hereditary in narure or acquired by way of a viral vector) then an amplification technique could be applied to determine the sequence and conformation of the abnormal component . In use
Figure 5 shows an embodiment of the present invention in use. In Figure 5 a keratin sample 16 can be collected from a subject at a pharmacy 26 . The keratin sample 16 can then be sent to a testing laboratory 34 so as to perform the method for detecting the presence of an abnormal component in the keratin sample 16 as seen in Figure 1.
A test kit 28 can be obtained so as to use the test kit 28 embodying the method of detection at the subject's home 30, in association with consultation of the subject's health care practitioner located at a health care clinic 32.
Alternatively, without the need of a home test the subject 11 can visit his or her health care clinic 32 so as to provide the keratin sample 16. The health care clinic 32 can perform the method of analyzing the keratin sample 16 themselves or in a further, preferred embodiment. τ.he health care clinic 32 can obtain the keratin sample 16 from the subject 11 so as to forward the keratin sample 16 to the testing laboratory 34.
Whilst the embodiments above have been restricted to members of a mammalian species, it is conceivable that any animal which exhibits keratin changes that are causatively linked to the presence of pathology can be the subject of testing using a method according to the present invention.
Further Embodiment
Organic Acid Treatment of Hair Fibers
It is known that immersion of hair fibers in organic acids such as formic acid and acetic acid can cause them to swell in diameter by as much as 50% and this effecr can be reversed by rinsing in water. Blackburn and Lowther (Blackburn S and Lowther AG. The action of organic acids on some fibrous proteins: the oxidation of wool keratin. Biochem J. 1951; 49 : 554-9) reported that a small amount of protein could be extracted from wool fibers by treatment in either formic or acetic acid at room temperature. This methodology was applied to several hair fibers from individuals of known pathology to determine if the ring observed by Synchrotron Small Angle X-Ray Scatter (SAXS) of hair, specific for the presence of breast cancer, could be removed by such treatment. Hair fibers from subjects with breast cancer were immersed in an 85% (v/v) solution of formic acid or in glacial acetic acid for 3 minutes at room temperature. The acid was then decanted and replaced with several changes of Milli-Q water. The fibers were allowed to dry then mounted into a sample holder for exposure to an X-ray source. SAXS image data was collected for these hairs .
Hair fibers that were taken from the same individual and subsequently treated with formic and acetic acid showed either significant reduction or complete removal of the ring in the zone of interest in the SAXS image. A typical example is demonstrated in Figure 6. Figure 6A is a SAXS image of a hair from an individual with breast cancer. Figures 6B and 6C are SAXS images of hair fibers from the same individual post treatment with acetic acid and formic acid respectively. It can be seen from these images that the ring in the zone of interest is significantly diminished after treatment with either acid and hence such treatments may be used as a tool to investigate the underlying change in the fiber associated with the presence of breast cancer.

Claims

1. A method for detecting a presence of an abnormal component in a keratin sample taken from a subject suffering from a pathological state comprising the steps of:
a) exposing the keratin sample to a swelling substance so as to penetrate the keratin sample thereby producing a derived chemical substance;
b) obtaining data from the derived chemical substance;
c) comparing the data obtained from the derived chemical substance with a second group of data contained in a reference database so as to identify the presence of the abnormal component in the keratin sample;
whereby detection of the abnormal component is consistenr with a presence of the pathological state in the subject.
2. The method for detecting the presence of an abnormal component in a keratin sample as recited in claim 1 wherein the swelling substance includes formic acid.
3. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims claim 1-2 wherein the second group of data is correlated with the presence of the pathological state in the subject.
4. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims 1-3 wherein the second group of data is causatively associated with the presence of the pathological state in the subject.
5. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims 1-4 wherein the swelling substance is selected from a plurality of different swelling substances.
6. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims 1-5 wherein the keratin sample is selected from a plurality of different keratin samples .
7. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims 1-6 wherein the second group of data is selected from a plurality of different data groups of data.
8. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims 1-7 wherein the derived data and the second group of data are analyzed using a plurality of different methods of comparison.
9. The method for detecting the presence of an abnormal component in a keratin sample as recited in any one of claims 1-8 wherein, in use, the keratin sample can be obtained and analyzed in association with at least one of a pharmacy, a test kit, the subject's home, a health care clinic and a testing laboratory.
10. A method for detecting the presence of an abnormal component in a keratin sample comprising the steps substantially as illustrated and described in the body of the specification.
11. The method for detecting the presence of an abnormal component in a keratin sample according to any one of the above claims wherein the subject is selected from the group consisting of a human, and an animal.
PCT/AU2007/000879 2006-06-29 2007-06-27 Improved process WO2008000020A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2009516820A JP2009541747A (en) 2006-06-29 2007-06-27 Improved method
AU2007264394A AU2007264394B2 (en) 2006-06-29 2007-06-27 Improved process
BRPI0713885-7A BRPI0713885A2 (en) 2006-06-29 2007-06-27 improved process
ES07719118T ES2371368T3 (en) 2006-06-29 2007-06-27 DETECTION OF AN ABNORMAL CHANGE IN THE COMPONENT OF A SAMPLE OF HAIR IN SUBJECTS WHO SUFFER BREAST CANCER.
CA002652955A CA2652955A1 (en) 2006-06-29 2007-06-27 Improved process
AT07719118T ATE520345T1 (en) 2006-06-29 2007-06-27 DETECTION OF AN ABNORMAL CHANGE IN THE COMPONENT OF A HAIR SAMPLE FROM BREAST CANCER PATIENTS
EP07719118A EP2032031B1 (en) 2006-06-29 2007-06-27 Detection of an abnormal change in the component of a hair sample in subjects suffering from breast cancer
KR1020097001887A KR101087576B1 (en) 2006-06-29 2007-06-27 Improved process
US12/306,134 US20090325303A1 (en) 2006-06-29 2007-06-27 Process
CNA2007800243800A CN101478916A (en) 2006-06-29 2007-06-27 Improved process

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2006903508A AU2006903508A0 (en) 2006-06-29 Improved Process
AU2006903508 2006-06-29
AU2007900272A AU2007900272A0 (en) 2007-01-19 Improved Process
AU2007900272 2007-01-19
AU2007900308 2007-01-22
AU2007900308A AU2007900308A0 (en) 2007-01-22 Improved Process

Publications (1)

Publication Number Publication Date
WO2008000020A1 true WO2008000020A1 (en) 2008-01-03

Family

ID=38845029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2007/000879 WO2008000020A1 (en) 2006-06-29 2007-06-27 Improved process

Country Status (13)

Country Link
US (1) US20090325303A1 (en)
EP (1) EP2032031B1 (en)
JP (1) JP2009541747A (en)
KR (1) KR101087576B1 (en)
CN (1) CN101478916A (en)
AR (1) AR061732A1 (en)
AT (1) ATE520345T1 (en)
AU (1) AU2007264394B2 (en)
BR (1) BRPI0713885A2 (en)
CA (1) CA2652955A1 (en)
ES (1) ES2371368T3 (en)
TW (1) TW200801513A (en)
WO (1) WO2008000020A1 (en)

Cited By (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009043115A1 (en) * 2007-10-04 2009-04-09 Fermiscan Australia Pty Limited Method for identifying biomarkers which are diagnostic for a pathological condition
WO2009135902A2 (en) 2008-05-07 2009-11-12 Vestas Wind Systems A/S A sectional blade
WO2011000020A1 (en) * 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
WO2011067465A1 (en) 2009-12-04 2011-06-09 Kristiina Rajala Formulations and methods for culturing stem cells
WO2011104644A1 (en) 2010-02-24 2011-09-01 Koninklijke Philips Electronics N.V. Hid lighting system
WO2011104713A1 (en) 2010-02-25 2011-09-01 Nova Measuring Instruments Ltd. Method and system for measurng in patterned structures
WO2011116811A1 (en) 2010-03-24 2011-09-29 Telefonaktiebolaget Lm Ericsson (Publ) A node with an improved back up protocol
WO2012043067A1 (en) 2010-09-27 2012-04-05 日本電気株式会社 Vehicle-mounted device and congestion control method
WO2012043801A1 (en) 2010-09-30 2012-04-05 積水メディカル株式会社 Patch
EP2440937A1 (en) * 2009-06-12 2012-04-18 SBC Research Pty Ltd A diagnostic method
WO2012070099A1 (en) 2010-11-22 2012-05-31 東芝三菱電機産業システム株式会社 Rolling mill control device
US8437570B2 (en) 2008-05-23 2013-05-07 Microsoft Corporation Geodesic image and video processing
US8435428B2 (en) 2007-02-21 2013-05-07 Air Liquide Electronics U.S. Lp Methods for forming a ruthenium-based film on a substrate
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8437858B2 (en) 2008-03-18 2013-05-07 Imi Intelligent Medical Implants, Ag Visual prosthesis system for displaying video image and text data
US8436491B2 (en) 2009-11-30 2013-05-07 Broadcom Corporation Low pin count wireless power IC
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
US8437177B2 (en) 2011-01-20 2013-05-07 Panasonic Corporation Nonvolatile latch circuit and nonvolatile flip-flop circuit
US8435648B2 (en) * 2008-12-30 2013-05-07 Cheil Industries, Inc. Pyridinylene ring compound for organic optoelectronic device, organic light emitting diode including the same and display including the organic light emitting diode
US8437394B2 (en) 2008-09-25 2013-05-07 Mediatek Inc. Adaptive filter
US8437308B2 (en) 2009-11-05 2013-05-07 Telefonaktiebolaget L M Ericsson (Publ) Handover measurements in a mobile communication system
US8435107B2 (en) 2005-07-06 2013-05-07 Wms Gaming Inc. Wagering game system with networked gaming devices
US8436944B2 (en) 2009-10-01 2013-05-07 Panasonic Corporation Wireless communications system, adaptor apparatus for video apparatus, video apparatus and control method for wireless communications system
US8435961B2 (en) 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US8434718B2 (en) 2009-09-02 2013-05-07 Eurocopter Reusable rotorcraft bumper, and a rotorcraft having such a bumper
US8436334B2 (en) 2007-10-12 2013-05-07 Agency For Science, Technology And Research Fabrication of phosphor free red and white nitride-based LEDs
US8434719B2 (en) 2008-03-13 2013-05-07 Patria Acostructures Oy Leading edge element of aircraft, method for manufacturing one, wing and stabilizer
US8435766B2 (en) 2009-03-19 2013-05-07 N.V. Desmet Ballestra Engineering S.A. Enzymatic oil recuperation process
US8435995B2 (en) 2009-02-05 2013-05-07 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US8435987B2 (en) 2007-05-07 2013-05-07 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
US8436791B2 (en) * 2009-01-26 2013-05-07 Seiko Epson Corporation Light-emitting device and mobility compensating method for driving the same, and electronic device
US8436762B2 (en) 2008-01-31 2013-05-07 Bae Systems Information And Electronic Systems Integration Inc. Determining at least one coordinate of an object using intersecting surfaces
US8437083B2 (en) 2009-05-21 2013-05-07 Canon Kabushiki Kaisha Optical element, optical system including the optical element, and optical apparatus including the optical system
US8436413B2 (en) 2008-10-15 2013-05-07 Indian Institute Of Technology, Bombay Nonvolatile floating gate analog memory cell
US8436270B2 (en) 2008-12-22 2013-05-07 Hypertherm, Inc. Method and apparatus for cutting high quality internal features and contours
US8435207B2 (en) 2006-11-06 2013-05-07 Aardvark Medical, Inc. Irrigation and aspiration devices and methods
US8435409B2 (en) 2010-05-28 2013-05-07 Ecolab Usa Inc. Activated sludge process in wastewater treatment
US8435560B2 (en) 2006-12-28 2013-05-07 Dow Corning Corporation Polynuclear microcapsules
US8437963B2 (en) 2008-02-08 2013-05-07 Annica Önell Method, computer program product and system for enabling clinical decision support
US8436875B2 (en) 2008-11-13 2013-05-07 Sharp Kabushiki Kaisha Display device
US8436054B2 (en) 2008-12-23 2013-05-07 E I Du Pont De Nemours And Company Fluorinated ionomer produced by aqueous polymerization using dispersed particulate of fluorinated ionomer produced in situ
US8436200B2 (en) 2008-11-18 2013-05-07 Takeda Pharmaceutical Company Limited Process for making (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4- iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione and intermediates thereof
US8437773B2 (en) 2009-12-09 2013-05-07 Qualcomm Incorporated Hierarchical information dissemination for location based systems
US8437286B2 (en) 2007-02-22 2013-05-07 Zte (Usa) Inc. Signaling for multi-hop relay in wireless communication systems
US8437228B2 (en) 2008-08-06 2013-05-07 Hitachi, Ltd. Thermally-assisted magnetic recording head
US8435960B2 (en) 1998-12-30 2013-05-07 Lakewood-Amedex, Inc. Devices for improved wound management
US8436820B2 (en) 2008-12-04 2013-05-07 Electronics And Telecommunications Research Institute Touchpad using resistive electro-conductive fiber and input device having the same
US8434703B2 (en) 2008-02-15 2013-05-07 E2V Technologies (Uk) Limited Apparatus and method for comminution of mineral ore
US8435540B2 (en) 2005-04-06 2013-05-07 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO
US8434372B2 (en) 2008-09-12 2013-05-07 Fras Technology As Fluid analysis system and method for operation of an analysis system
US8438479B2 (en) 2008-11-25 2013-05-07 Panasonic Corporation Operation support apparatus and method of the same
US8437224B2 (en) * 2006-08-03 2013-05-07 Wfs Technologies Ltd. Underwater communications
US8435476B2 (en) 2006-08-03 2013-05-07 Spawnt Private S.A.R.L. Process for supplying a fuel cell with hydrogen by means of silanes or polysilanes
US8436134B2 (en) 2008-07-18 2013-05-07 University Of Chicago Semiconducting polymers
US8437114B2 (en) 2008-11-26 2013-05-07 Murata Manufacturing Co., Ltd. ESD Protection Device
US8435275B2 (en) 2011-03-30 2013-05-07 Valkee Oy Portable ear light device
US8434242B2 (en) 2010-09-16 2013-05-07 Velico Medical, Inc. Spray dried human plasma
US8434183B2 (en) 2010-08-13 2013-05-07 Braun Gmbh Brush section for an electric toothbrush
US8436312B2 (en) * 2008-10-08 2013-05-07 National Institute Of Radiological Sciences DOI type radiation detector
US8437069B2 (en) 2008-03-11 2013-05-07 Sipix Imaging, Inc. Luminance enhancement structure for reflective display devices
US8435928B2 (en) 2007-07-13 2013-05-07 Ishihara Sangyo Kaisha, Ltd. Herbicidal composition
US8437827B2 (en) 2009-06-30 2013-05-07 Abbott Diabetes Care Inc. Extruded analyte sensors and methods of using same
US8435513B2 (en) 2008-07-08 2013-05-07 Oncomed Pharmaceuticals, Inc. NOTCH1 receptor antibodies and methods of treatment
US8435914B2 (en) 2009-05-14 2013-05-07 Univation Technologies, Llc Mixed metal catalyst systems having a tailored hydrogen response
US8436060B2 (en) 2010-03-30 2013-05-07 Samsung Electronics Co., Ltd. Organic aerogel and composition for the organic aerogel
US8436918B2 (en) 2009-02-27 2013-05-07 Deluxe Laboratories, Inc. Systems, apparatus and methods for subtitling for stereoscopic content
US8438600B2 (en) 2009-08-20 2013-05-07 Lg Electronics Inc. Method of processing EPG metadata in network device and network device for controlling the same
US8435246B2 (en) 2009-11-02 2013-05-07 Synvasive Technology, Inc. Knee arthroplasty apparatus and method
US8438616B2 (en) 2008-09-28 2013-05-07 Huawei Technologies Co., Ltd. Method for terminal configuration and management and terminal device
US8436092B2 (en) 2009-01-16 2013-05-07 Tsinghua University Giant magnetoresistance composite material containing carbon nanotubes
US8435454B2 (en) 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
US8438272B2 (en) 2010-08-31 2013-05-07 Sap Ag Methods and systems for managing quality of services for network participants in a networked business process
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US8436383B2 (en) * 2010-02-17 2013-05-07 Lg Innotek Co., Ltd. Light emitting device, light emitting device package, and lighting system
US8434488B2 (en) 2009-06-08 2013-05-07 Covidien Lp Endotracheal tube with dedicated evacuation port
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
US8438020B2 (en) 2007-10-12 2013-05-07 Panasonic Corporation Vector quantization apparatus, vector dequantization apparatus, and the methods
US8437597B2 (en) 2009-06-19 2013-05-07 Corning Cable Systems Llc Mounting of fiber optic cable assemblies within fiber optic shelf assemblies
US8435997B2 (en) 2007-08-10 2013-05-07 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
US8435770B2 (en) 2007-05-09 2013-05-07 Mascoma Corporation Gene knockout mesophilic and thermophilic organisms, and methods of use thereof
US8434344B2 (en) * 2007-12-12 2013-05-07 Service Solutions U.S. Llc Verification of scale calibration method and apparatus
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US8436028B2 (en) 2007-06-20 2013-05-07 Merck Sharp & Dohme Corp CETP inhibitors derived from benzoxazole arylamides
US8435828B2 (en) 2010-01-13 2013-05-07 Renesas Electronics Corporation Method of manufacturing semiconductor device
US8434872B2 (en) 2007-07-30 2013-05-07 National Institute Of Information And Communications Technology Multi-viewpoint floating image display device
US8435785B2 (en) 2005-06-01 2013-05-07 Wisconsin Alumni Research Foundation Method of forming dendritic cells from embryonic stem cells
US8436053B2 (en) 2008-12-23 2013-05-07 E.I. Du Pont De Nemours And Company Fluorinated ionomer produced by aqueous polymerization using dispersed particulate of fluorinated ionomer
US8437845B2 (en) 2007-02-01 2013-05-07 Ls Biopath, Inc. Electrical methods for detection and characterization of abnormal tissue and cells
US8438044B2 (en) 2011-01-18 2013-05-07 Audiahealth, Llc Systems and methods combining print and audio technologies to deliver and personalize health information
US8435978B2 (en) * 2006-09-29 2013-05-07 Gruenenthal Gmbh Substituted sulfonamide compounds
US8436444B2 (en) * 2008-12-10 2013-05-07 Si-Nano Inc. Thin film photoelectric conversion device and method for manufacturing thin film photoelectric conversion device
US8435768B2 (en) 2009-01-30 2013-05-07 Ajinomoto Co., Inc. Method for producing succinic acid using a yeast belonging to the genus Yarrowia
US8436078B2 (en) * 2008-04-28 2013-05-07 Kuraray Noritake Dental Inc. Dental composition and composite resin
US8436011B2 (en) 2008-07-08 2013-05-07 Sanofi Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
US8436158B2 (en) 2008-06-18 2013-05-07 Pfizer Inc. Antibodies to IL-6 and their uses
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US8436546B2 (en) 2006-10-20 2013-05-07 Luxim Corporation Electrodeless lamps and methods
US8438452B2 (en) 2008-12-29 2013-05-07 Intel Corporation Poison bit error checking code scheme
US8435742B2 (en) 2007-11-01 2013-05-07 Yamaguchi University Method and kit for detection/quantification of target RNA
US8434659B2 (en) * 2008-10-14 2013-05-07 Hesse & Knipps Gmbh Bonding device, ultrasonic transducer, and bonding method
US8435289B2 (en) 2005-02-11 2013-05-07 Abbott Medical Optics Inc. Rapid exchange IOL insertion apparatus and methods of using
US8437247B2 (en) 2008-10-31 2013-05-07 Htc Corporation Methods of packet element transmission in wireless communications system
US8436862B2 (en) 2008-12-11 2013-05-07 Nvidia Corporation Method and system for enabling managed code-based application program to access graphics processing unit
US8434972B2 (en) 2007-02-17 2013-05-07 Hartmetall-Werkzeugfabrik Paul Horn Gmbh Broaching tool, in particular keyway broaching tool
US8435986B2 (en) 2008-08-14 2013-05-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Bicyclic traizole derivatives for treating of tumors
US8435272B2 (en) 2009-04-09 2013-05-07 Arthrex, Inc. Clavicle nail with locking end cap
US8435341B2 (en) 2009-11-03 2013-05-07 Agfa-Gevaert N.V. Preparing and dispersing surface-modified colour pigments
US8437594B2 (en) 2010-03-16 2013-05-07 Furukawa Electric Co., Ltd. Holey fiber
US8434893B2 (en) 2007-10-17 2013-05-07 Lsi Industries, Inc. Luminaire and methods of use
US8434605B2 (en) 2008-06-06 2013-05-07 Nsk-Warner K.K. One-way clutch of roller type for starter of motor bike
US8435552B2 (en) 2007-02-09 2013-05-07 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US8435769B2 (en) 2007-04-13 2013-05-07 Monsanto Technology Llc Use of glyphosate to produce shikimic acid in microorganisms
US8437173B2 (en) 2010-03-19 2013-05-07 Panasonic Corporation Nonvolatile memory element, manufacturing method thereof, design support method therefor, and nonvolatile memory device
US8437057B2 (en) 2007-05-16 2013-05-07 Seereal Technologies S.A. Method for rendering and generating color video holograms in real time
US8435636B2 (en) 2007-03-29 2013-05-07 Akron Polymer Systems, Inc. Optical compensation films of brominated styrenic polymers and related methods
US8435383B2 (en) 2006-08-25 2013-05-07 Edwin X Graf Process and machine for making air dried tissue
US8437357B2 (en) 2007-05-29 2013-05-07 Packetfront Network Products Ab Method of connecting VLAN systems to other networks via a router
US8434647B2 (en) 2009-08-08 2013-05-07 Riad Aamar Device for measuring and dispensing a prescribed amount of liquid
US8436157B2 (en) 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
US8435276B2 (en) 2006-02-27 2013-05-07 Thomas Perez Method and apparatus for the combined application of light therapy, optic diagnosis, and fluid to tissue
US8434311B2 (en) 2006-11-01 2013-05-07 Alstom Technology Ltd. System for controlling a combustion process for a gas turbine
US8437951B2 (en) 2009-09-14 2013-05-07 Research In Motion Limited Methods, device and systems for determining route metrics using stored route information
US8435751B2 (en) 2008-09-25 2013-05-07 Gambro Lundia Ab Membrane for cell expansion
US8435968B2 (en) 2008-09-19 2013-05-07 Pimco 2664 Limited Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US8436754B2 (en) 2009-03-27 2013-05-07 Huawei Technologies Co., Ltd. Encoding and decoding method and device
US8436069B2 (en) 2009-03-30 2013-05-07 Fujifilm Corporation Ink composition
US8435064B2 (en) 2009-02-12 2013-05-07 Fronius International Gmbh Mounting for a DC-AC converter and method for fitting a DC-AC converter
US8435539B2 (en) 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435745B2 (en) 2005-02-14 2013-05-07 Zymogenetics, Inc. Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
US8436185B2 (en) 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US8435209B2 (en) 2009-12-30 2013-05-07 Medtronic Minimed, Inc. Connection and alignment detection systems and methods
US8435459B2 (en) 2003-01-07 2013-05-07 Micropyretics Heaters International, Inc. Heating and sterilizing apparatus and method of using same
US8437792B2 (en) 2007-02-14 2013-05-07 Qualcomm Incorporated Uplink power control for LTE
US8436698B2 (en) 2009-11-02 2013-05-07 Harris Corporation MEMS-based tunable filter
US8438231B2 (en) 2010-01-08 2013-05-07 Alcatel Lucent Telecommunication messaging through a social networking service
US8435545B2 (en) * 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum
US8434323B2 (en) 2008-07-14 2013-05-07 Johnson Controls Technology Company Motor cooling applications
US8435555B2 (en) 2008-05-01 2013-05-07 Eminate Limited Salt product
US8437418B2 (en) 2008-04-30 2013-05-07 Huawei Technologies Co., Ltd. Method and apparatus for detecting signals of multi-input multi-output system
US8435524B2 (en) 2008-07-16 2013-05-07 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8436342B2 (en) 2009-01-12 2013-05-07 Samsung Display Co., Ltd. Organic light emitting display device and method of manufacturing the same
US8437997B2 (en) 2008-01-22 2013-05-07 Exxonmobil Upstream Research Company Dynamic connectivity analysis
US8434308B2 (en) 2009-09-15 2013-05-07 General Electric Company Heat pipes for transferring heat to an organic rankine cycle evaporator
US8435402B2 (en) * 2010-03-29 2013-05-07 Marathon Canadian Oil Sands Holding Limited Nozzle reactor and method of use
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US8436156B2 (en) 2008-01-04 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US8436614B2 (en) 2008-12-17 2013-05-07 Siemens Aktiengesellschaft Local coil arrangement for magnetic resonance applications with activatable marker
US8434524B2 (en) 2011-01-31 2013-05-07 Vanderbilt University Elastic hydraulic accumulator/reservoir system
US8435761B2 (en) 2006-06-29 2013-05-07 Ucb Pharma Sa DNA encoding antibody molecules which bind human IL-17
US8437964B2 (en) 2005-12-19 2013-05-07 Analiza, Inc. Systems and methods involving data patterns such as spectral biomarkers
US8436833B2 (en) 2009-11-25 2013-05-07 Corning Incorporated Methods and apparatus for sensing touch events on a display
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US8435446B2 (en) 2007-07-25 2013-05-07 Alcoa Inc. Surfaces and coatings for the removal of carbon dioxide
US8436008B2 (en) 2008-12-22 2013-05-07 Incyte Corporation Substituted heterocyclic compounds
US8435228B2 (en) 2009-08-12 2013-05-07 Medrad, Inc. Interventional catheter assemblies incorporating guide wire brake and management systems
US8436235B2 (en) 2001-11-13 2013-05-07 U.S. Smokeless Tobacco Company Cloning of cytochrome p450 genes from Nicotiana
US8434716B2 (en) 2006-01-19 2013-05-07 The Boeing Company Compliant crown panel for an aircraft
US8434781B2 (en) 2009-04-16 2013-05-07 Doona Holdings Ltd Baby safety car seat convertible into a rollable baby seat
US8436488B2 (en) * 2009-03-03 2013-05-07 Bluewater Energy Services B.V. Semi-direct variable speed drive with N+1 power availability
US8434889B2 (en) 2010-03-19 2013-05-07 GE Lighting Solutions, LLC Lighted display case having reduced glare
US8435775B2 (en) 2006-09-06 2013-05-07 Medical Research Council Mutant Pfu DNA polymerase
US8436002B2 (en) 2009-10-23 2013-05-07 Eli Lilly And Company AKT inhibitors
US8434383B2 (en) 2009-12-04 2013-05-07 Hyundai Motor Company Transmission shifting apparatus for vehicle
US8437962B2 (en) 2009-11-25 2013-05-07 Halliburton Energy Services, Inc. Generating probabilistic information on subterranean fractures
US8435319B2 (en) 2007-12-07 2013-05-07 Cedric Dackam Filter unit for the filtration of gaseous fluids, in particular air filter in internal combustion engines
US8436024B2 (en) 2009-10-02 2013-05-07 Astrazeneca Ab 2-pyridone compounds
US8436537B2 (en) 2008-07-07 2013-05-07 Samsung Sdi Co., Ltd. Substrate structure for plasma display panel, method of manufacturing the substrate structure, and plasma display panel including the substrate structure
US8436149B2 (en) 2006-10-27 2013-05-07 Abbvie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
US8434913B2 (en) 2008-05-30 2013-05-07 Koninklijke Philips Electronics N.V. Round illumination device
US8437857B2 (en) 2008-09-04 2013-05-07 Boston Scientific Neuromodulation Corporation Multiple tunable central cathodes on a paddle for increased medial-lateral and rostral-caudal flexibility via current steering
US8435313B2 (en) 2008-05-19 2013-05-07 Furanix Technologies, B.V. Fuel composition
US8436510B2 (en) * 2008-04-30 2013-05-07 Murata Manufacturing Co., Ltd. Boundary acoustic wave device
US8434184B2 (en) 2010-08-13 2013-05-07 Braun Gmbh Fracture resistant brush head
US8434910B2 (en) 2010-06-01 2013-05-07 Lg Innotek Co., Ltd. Light emitting device package and lighting system
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US8434522B2 (en) 2007-05-31 2013-05-07 Tokyo Electron Limited Fluid control apparatus
US8434195B2 (en) 2007-04-05 2013-05-07 Siemens Ag Österreich Door rail and door attachment system for passenger rail cars
US8435556B2 (en) 2000-12-22 2013-05-07 Alltranz, Llc Transdermal delivery of cannabidiol
US8438210B2 (en) 2009-05-04 2013-05-07 Comcast Cable Communications, Llc Sharing media content based on a media server
US8436172B2 (en) 2009-08-31 2013-05-07 Udc Ireland Limited Material selecting method upon purifying iridium complex by sublimation
US8437183B2 (en) 2009-12-16 2013-05-07 Sandisk Il Ltd. Auxiliary parity bits for data written in multi-level cells
US8434285B2 (en) 2007-01-19 2013-05-07 Steven L. Harrison Tiled transition bracketing
US8437293B2 (en) 2007-06-19 2013-05-07 Telefonaktiebolaget L M Ericsson (Publ) Methods and systems for scheduling resources in a telecommunication system
US8436036B2 (en) 2009-04-24 2013-05-07 Janssen R&D Ireland Diaryl ethers
US8435342B2 (en) 2009-12-15 2013-05-07 Shell Oil Company Concrete composition
US8437970B2 (en) 2009-06-05 2013-05-07 Apple Inc. Restoring and storing magnetometer calibration data
US8435752B2 (en) 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
US8435325B2 (en) 2008-10-23 2013-05-07 Hitachi, Ltd. Method and device for removing CO2 and H2S
US8434906B2 (en) 2010-02-23 2013-05-07 General Electric Company Lighting system with thermal management system
US8436925B2 (en) 2008-12-08 2013-05-07 Sony Corporation Solid-state imaging device, method for processing signal of solid-state imaging device, and imaging apparatus
US8435355B2 (en) 2008-12-29 2013-05-07 Weyerhaeuser Nr Company Fractionation of lignocellulosic material using ionic liquids
US8436459B2 (en) 2008-11-28 2013-05-07 Mitsubishi Electric Corporation Power semiconductor module
US8435119B2 (en) 2007-12-26 2013-05-07 Scientific Games Holdings Limited User-controlled sweepstakes entries
US8438021B2 (en) 2009-10-15 2013-05-07 Huawei Technologies Co., Ltd. Signal classifying method and apparatus
US8436182B2 (en) 2008-05-23 2013-05-07 Zaklady Farmaceutyczne Polpharma Sa Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity
US8436213B2 (en) 2008-10-10 2013-05-07 Exxonmobil Chemical Patents Inc. Process for producing phenol and methyl ethyl ketone
US8437882B2 (en) * 2010-02-17 2013-05-07 Inscope Energy, Llc Managing power utilized within a local power network
US8435792B2 (en) 2010-01-14 2013-05-07 Baxter International Inc. Methods and compositions for treating bleeding disorders
US8437794B2 (en) 2010-01-28 2013-05-07 Alcatel Lucent Methods of determining uplink target signal-to-interfence-and-noise ratios and systems thereof
US8436171B2 (en) 2008-02-01 2013-05-07 Akinion Pharmaceuticals Ab Amino substituted pyrazines as inhibitors or protein kinases
US8434776B2 (en) 2010-08-16 2013-05-07 Andy WUTHRICH Bicycle frame with rear suspension system
US8435002B2 (en) 2004-08-30 2013-05-07 Lord Corporation Helicopter vibration control system and rotating assembly rotary forces generators for canceling vibrations
US8435778B2 (en) 2010-05-13 2013-05-07 Suntory Holdings Limited Gene encoding lignan methyltransferase and use thereof
US8435917B2 (en) 2008-12-23 2013-05-07 Sued-Chemie Catalysts Italia S.R.L. Ammonia oxidation catalysts
US8436110B2 (en) 2008-10-31 2013-05-07 Dow Global Technologies Llc Olefin metathesis process employing bimetallic ruthenium complex with bridging hydrido ligands
US8437806B2 (en) 2009-03-03 2013-05-07 Lg Electronics Inc. Mobile terminal and method for displaying data in mobile terminal
US8437079B2 (en) 2011-05-06 2013-05-07 Leapers, Inc. Apparatus including a reticle, assembly and method for operating the same
US8434422B2 (en) 2009-04-20 2013-05-07 Dow Global Technologies Llc Coating apparatus and method
US8436512B2 (en) 2010-04-06 2013-05-07 Senseor Method of rapidly interrogating elastic wave sensors
US8435999B2 (en) 2007-08-13 2013-05-07 Monsanto Technology Llc Compositions and methods for controlling nematodes
US8436436B2 (en) 2006-08-01 2013-05-07 Washington University Multifunctional nanoscopy for imaging cells
US8436218B2 (en) 2010-05-27 2013-05-07 Honeywell International Inc. Azeotrope-like composition of hexafluoropropane, hexafluoropropene and hydrogen fluoride
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8434460B2 (en) 2010-10-29 2013-05-07 Ford Global Technologies, Llc Integrally molded carbon canister
US8435486B2 (en) * 2010-05-24 2013-05-07 Toyota Jidosha Kabushiki Kaisha Redox material for thermochemical water splitting, and method for producing hydrogen
US8435721B2 (en) 2008-02-21 2013-05-07 Nissan Chemical Industries, Ltd. Resist underlayer film forming composition and forming method of resist pattern using the same
US8436102B2 (en) 2009-07-06 2013-05-07 Denki Kagaku Kogyo Kabushiki Kaisha Polychloroprene latex composition, process for production of same, and products of forming thereof
US8437527B2 (en) 2010-06-16 2013-05-07 Hitachi Aloka Medical, Ltd. Ultrasound diagnostic apparatus
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US8436205B2 (en) 2008-10-23 2013-05-07 Actelion Pharmaceuticals Ltd. Tetrahydronaphthalene compounds
US8434877B2 (en) 2009-08-20 2013-05-07 Canon Kabushiki Kaisha Illumination optical system and projection display apparatus
US8436163B2 (en) 2000-05-04 2013-05-07 Avi Biopharma, Inc. Splice-region antisense composition and method
US8435992B2 (en) 2008-05-16 2013-05-07 Pharma Mar S.A. Multiple myeloma treatments
US8437278B2 (en) 2009-07-02 2013-05-07 Seiko Epson Corporation Service providing apparatus for digital processing service, wireless communication system, and wireless communication method
US8437712B2 (en) 2005-10-27 2013-05-07 Telecom Italia S.P.A. Method and system for multiple antenna communications using multiple transmission modes, related apparatus and computer program product
US8434914B2 (en) 2009-12-11 2013-05-07 Osram Sylvania Inc. Lens generating a batwing-shaped beam distribution, and method therefor
US8436755B2 (en) 2010-05-21 2013-05-07 Research In Motion Limited Methods and devices for reducing sources in binary entropy coding and decoding
US8436114B2 (en) 2010-10-21 2013-05-07 Exxonmobil Chemical Patents Inc. Polyethylene and process for production thereof
US8435771B2 (en) 2008-05-07 2013-05-07 Novozymes A/S Fermentation of a lignocellulose-containing material
US8435415B2 (en) 2009-11-24 2013-05-07 The United States of America, as represented by the Secretary of Commerce, The National Institute of Standards and Technology Nanofabrication process and nanodevice
US8436090B2 (en) 2008-09-16 2013-05-07 Nippon Shokubai Co., Ltd. Production method and method for enhancing liquid permeability of water-absorbing resin
US8435725B2 (en) 2007-09-20 2013-05-07 Agfa-Gevaert Nv Security laminates with interlaminated transparent embossed polymer hologram
US8434236B2 (en) * 2007-02-26 2013-05-07 Pellenc (Societe Anonyme) Chain saw with tension adjustment
US8436065B2 (en) 2010-04-01 2013-05-07 Samsung Electronics Co., Ltd. Aerogel, and composition and method for manufacture of the aerogel
US8434190B2 (en) 2008-09-01 2013-05-07 Braun Gmbh Toothbrush and method of manufacturing it
US8437798B2 (en) 2009-04-27 2013-05-07 Motorola Mobility Llc Uplink scheduling support in multi-carrier wireless communication systems
US8434581B2 (en) 2008-12-19 2013-05-07 Zf Friedrichshafen Ag Suspension device having anti-roll compensation
US8437332B2 (en) 2009-06-22 2013-05-07 Qualcomm Incorporated Low complexity unified control channel processing
US8436001B2 (en) 2010-04-07 2013-05-07 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US8435701B2 (en) * 2007-11-27 2013-05-07 Southbourne Investments Ltd. Holographic recording medium
US8435554B2 (en) 2003-02-21 2013-05-07 Shin Nippon Biomedical Laboratories, Ltd. Compositons for nasal administration of pharmaceuticals
US8436295B2 (en) 2009-09-15 2013-05-07 Canon Anelva Corporation Device for measuring mean free path, vacuum gauge, and method for measuring mean free path
US8436137B2 (en) 2008-12-03 2013-05-07 Koji Kawakami Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide
US8434286B2 (en) 2010-03-03 2013-05-07 Yuyama Manufacturing Co., Ltd. Medicament dispensing machine
US8437067B2 (en) 2008-03-18 2013-05-07 Konica Minolta Holdings, Inc. Electrochemical display element
US8436035B2 (en) 2006-12-18 2013-05-07 Novartis Ag Organic compounds
US8435056B2 (en) 2009-04-16 2013-05-07 Enphase Energy, Inc. Apparatus for coupling power generated by a photovoltaic module to an output
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
EP2617794A2 (en) 2008-05-07 2013-07-24 E. I. du Pont de Nemours and Company Compositions comprising 2,3,3,3- tetrafluoropropene
EP2623491A2 (en) 2009-04-02 2013-08-07 Merck Patent GmbH Piperidine and piperazine derivatives as autotaxin inhibitors
WO2013124832A2 (en) 2012-02-24 2013-08-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2013128380A1 (en) 2012-02-28 2013-09-06 Koninklijke Philips N.V. Device for light based skin treatment
WO2013128369A1 (en) 2012-02-28 2013-09-06 Koninklijke Philips N.V. Aed with compression sensor
EP2637202A2 (en) 2007-09-28 2013-09-11 Tessera, Inc. Flip chip interconnection with etched posts on a microelectronic element joined to etched posts on a substrate by a fusible metal and corresponding manufacturing method
WO2013132448A1 (en) 2012-03-07 2013-09-12 Kba-Notasys Sa Method of checking producibility of a composite security design of a security document on a line of production equipment and digital computer environment for implementing the same
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
EP2796818A1 (en) 2013-04-22 2014-10-29 Shell Internationale Research Maatschappij B.V. Method and apparatus for producing a liquefied hydrocarbon stream
EP2796145A1 (en) 2013-04-22 2014-10-29 CSL Behring GmbH Complex
US9030001B2 (en) 2010-07-27 2015-05-12 Tessera, Inc. Microelectronic packages with nanoparticle joining
US9496236B2 (en) 2010-12-10 2016-11-15 Tessera, Inc. Interconnect structure
US9633971B2 (en) 2015-07-10 2017-04-25 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles
WO2019186577A1 (en) 2018-03-27 2019-10-03 Council Of Scientific And Industrial Research A non-invasive and remote method to screen cancer
US10535626B2 (en) 2015-07-10 2020-01-14 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090108605A (en) * 2007-01-12 2009-10-15 베로니카 제임스 Biometric diagnosis
WO2011119235A1 (en) * 2010-03-24 2011-09-29 Glendon John Parker Methods for conducting genetic analysis using protein polymorphism

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000034774A1 (en) * 1998-12-10 2000-06-15 Fiberscan Pty Ltd Using hair to screen for breast cancer
US6350582B1 (en) * 1987-12-28 2002-02-26 Psychemedics Corporation Hair analysis method
WO2003060513A2 (en) * 2002-01-04 2003-07-24 E2V Technologies Limited Method and apparatus for cancer detection
US20060024705A1 (en) * 2004-06-07 2006-02-02 Wella AG, Board of Regents of the University of Oklahoma and Molecular analysis of hair follicles for disease
CN1847846A (en) * 2005-04-14 2006-10-18 威尔基因科技股份有限公司 Hair detecting method for evaluating health status

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125880A (en) * 1998-08-21 2000-11-21 Fish Falk Method for the determination of analyte concentration in blood

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350582B1 (en) * 1987-12-28 2002-02-26 Psychemedics Corporation Hair analysis method
WO2000034774A1 (en) * 1998-12-10 2000-06-15 Fiberscan Pty Ltd Using hair to screen for breast cancer
WO2003060513A2 (en) * 2002-01-04 2003-07-24 E2V Technologies Limited Method and apparatus for cancer detection
US20060024705A1 (en) * 2004-06-07 2006-02-02 Wella AG, Board of Regents of the University of Oklahoma and Molecular analysis of hair follicles for disease
CN1847846A (en) * 2005-04-14 2006-10-18 威尔基因科技股份有限公司 Hair detecting method for evaluating health status

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AKSIROV A. ET AL.: "Biological and medical application of SR from the storage rings of VEPP-3 and "Siberia-2". The origin of specific changes of small X rax diffraction pattern of hair and their correlation with the elemental content", NUCLEAR INSTRUMENTS AND METHODS IN PHYSICS RESEARCH A, vol. 470, 2001, pages 380 - 387, XP004303843 *
FEUGHELMAN M. ET AL.: "Hexagonal Packing of Intermediate Filaments (Microfibrils) in alpha-Keratin Fibers", TEXTILE RESEARCH J., vol. 68, no. 2, 1998, pages 110 - 114, XP008103565 *
KIST A. ET AL.: "Mapping of ecologically unfavourable territories based on human hair composition", BIOLOGICAL TRACE ELEMENT RESEARCH, vol. 64, 1998, pages 1 - 12, XP008102018 *
LYMAN D. ET AL.: "Fourier Transform Infrared attenuated total reflection analysis of human hair: Comparison of hair from breast cancer patients with hair from healthy subjects", APPLIED SPECTROSCOP., vol. 59, no. 1, 2005, pages 26 - 32, XP008100668 *
TOWLER M. ET AL.: "Raman spectroscopy of the human nail: A potential tool for evaluating bone health", J. MATER. SCI.: MATER. MED., vol. 18, 2007, pages 759 - 763, XP019503691 *

Cited By (274)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435960B2 (en) 1998-12-30 2013-05-07 Lakewood-Amedex, Inc. Devices for improved wound management
US8436163B2 (en) 2000-05-04 2013-05-07 Avi Biopharma, Inc. Splice-region antisense composition and method
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
US8435556B2 (en) 2000-12-22 2013-05-07 Alltranz, Llc Transdermal delivery of cannabidiol
US8436235B2 (en) 2001-11-13 2013-05-07 U.S. Smokeless Tobacco Company Cloning of cytochrome p450 genes from Nicotiana
US8435459B2 (en) 2003-01-07 2013-05-07 Micropyretics Heaters International, Inc. Heating and sterilizing apparatus and method of using same
US8435554B2 (en) 2003-02-21 2013-05-07 Shin Nippon Biomedical Laboratories, Ltd. Compositons for nasal administration of pharmaceuticals
US8435539B2 (en) 2004-02-13 2013-05-07 Immunomedics, Inc. Delivery system for cytotoxic drugs by bispecific antibody pretargeting
US8435002B2 (en) 2004-08-30 2013-05-07 Lord Corporation Helicopter vibration control system and rotating assembly rotary forces generators for canceling vibrations
US8435289B2 (en) 2005-02-11 2013-05-07 Abbott Medical Optics Inc. Rapid exchange IOL insertion apparatus and methods of using
US8435745B2 (en) 2005-02-14 2013-05-07 Zymogenetics, Inc. Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
US8435540B2 (en) 2005-04-06 2013-05-07 Ibc Pharmaceuticals, Inc. Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO
US8435785B2 (en) 2005-06-01 2013-05-07 Wisconsin Alumni Research Foundation Method of forming dendritic cells from embryonic stem cells
US8435107B2 (en) 2005-07-06 2013-05-07 Wms Gaming Inc. Wagering game system with networked gaming devices
US8437712B2 (en) 2005-10-27 2013-05-07 Telecom Italia S.P.A. Method and system for multiple antenna communications using multiple transmission modes, related apparatus and computer program product
US8437964B2 (en) 2005-12-19 2013-05-07 Analiza, Inc. Systems and methods involving data patterns such as spectral biomarkers
US8434716B2 (en) 2006-01-19 2013-05-07 The Boeing Company Compliant crown panel for an aircraft
US8435276B2 (en) 2006-02-27 2013-05-07 Thomas Perez Method and apparatus for the combined application of light therapy, optic diagnosis, and fluid to tissue
US8435970B2 (en) 2006-06-29 2013-05-07 Astex Therapeutics Limited Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea
US8435761B2 (en) 2006-06-29 2013-05-07 Ucb Pharma Sa DNA encoding antibody molecules which bind human IL-17
US8436436B2 (en) 2006-08-01 2013-05-07 Washington University Multifunctional nanoscopy for imaging cells
US8437224B2 (en) * 2006-08-03 2013-05-07 Wfs Technologies Ltd. Underwater communications
US8435476B2 (en) 2006-08-03 2013-05-07 Spawnt Private S.A.R.L. Process for supplying a fuel cell with hydrogen by means of silanes or polysilanes
US8435383B2 (en) 2006-08-25 2013-05-07 Edwin X Graf Process and machine for making air dried tissue
US8435775B2 (en) 2006-09-06 2013-05-07 Medical Research Council Mutant Pfu DNA polymerase
US8435978B2 (en) * 2006-09-29 2013-05-07 Gruenenthal Gmbh Substituted sulfonamide compounds
US8436546B2 (en) 2006-10-20 2013-05-07 Luxim Corporation Electrodeless lamps and methods
US8436149B2 (en) 2006-10-27 2013-05-07 Abbvie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
US8434311B2 (en) 2006-11-01 2013-05-07 Alstom Technology Ltd. System for controlling a combustion process for a gas turbine
US8435207B2 (en) 2006-11-06 2013-05-07 Aardvark Medical, Inc. Irrigation and aspiration devices and methods
US8436035B2 (en) 2006-12-18 2013-05-07 Novartis Ag Organic compounds
US8435560B2 (en) 2006-12-28 2013-05-07 Dow Corning Corporation Polynuclear microcapsules
US8435752B2 (en) 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
US8434285B2 (en) 2007-01-19 2013-05-07 Steven L. Harrison Tiled transition bracketing
US8437845B2 (en) 2007-02-01 2013-05-07 Ls Biopath, Inc. Electrical methods for detection and characterization of abnormal tissue and cells
US8435552B2 (en) 2007-02-09 2013-05-07 Royal College Of Surgeons In Ireland Collagen/hydroxyapatite composite scaffold, and process for the production thereof
US8437792B2 (en) 2007-02-14 2013-05-07 Qualcomm Incorporated Uplink power control for LTE
US8434972B2 (en) 2007-02-17 2013-05-07 Hartmetall-Werkzeugfabrik Paul Horn Gmbh Broaching tool, in particular keyway broaching tool
US8435428B2 (en) 2007-02-21 2013-05-07 Air Liquide Electronics U.S. Lp Methods for forming a ruthenium-based film on a substrate
US8437286B2 (en) 2007-02-22 2013-05-07 Zte (Usa) Inc. Signaling for multi-hop relay in wireless communication systems
US8434236B2 (en) * 2007-02-26 2013-05-07 Pellenc (Societe Anonyme) Chain saw with tension adjustment
US8435984B2 (en) 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
US8435636B2 (en) 2007-03-29 2013-05-07 Akron Polymer Systems, Inc. Optical compensation films of brominated styrenic polymers and related methods
US8434195B2 (en) 2007-04-05 2013-05-07 Siemens Ag Österreich Door rail and door attachment system for passenger rail cars
US8435769B2 (en) 2007-04-13 2013-05-07 Monsanto Technology Llc Use of glyphosate to produce shikimic acid in microorganisms
US8435987B2 (en) 2007-05-07 2013-05-07 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
US8435770B2 (en) 2007-05-09 2013-05-07 Mascoma Corporation Gene knockout mesophilic and thermophilic organisms, and methods of use thereof
US8437057B2 (en) 2007-05-16 2013-05-07 Seereal Technologies S.A. Method for rendering and generating color video holograms in real time
US8437357B2 (en) 2007-05-29 2013-05-07 Packetfront Network Products Ab Method of connecting VLAN systems to other networks via a router
US8434522B2 (en) 2007-05-31 2013-05-07 Tokyo Electron Limited Fluid control apparatus
US8437293B2 (en) 2007-06-19 2013-05-07 Telefonaktiebolaget L M Ericsson (Publ) Methods and systems for scheduling resources in a telecommunication system
US8436028B2 (en) 2007-06-20 2013-05-07 Merck Sharp & Dohme Corp CETP inhibitors derived from benzoxazole arylamides
US8435928B2 (en) 2007-07-13 2013-05-07 Ishihara Sangyo Kaisha, Ltd. Herbicidal composition
US8435446B2 (en) 2007-07-25 2013-05-07 Alcoa Inc. Surfaces and coatings for the removal of carbon dioxide
US8434872B2 (en) 2007-07-30 2013-05-07 National Institute Of Information And Communications Technology Multi-viewpoint floating image display device
US8435997B2 (en) 2007-08-10 2013-05-07 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
US8435999B2 (en) 2007-08-13 2013-05-07 Monsanto Technology Llc Compositions and methods for controlling nematodes
US8435725B2 (en) 2007-09-20 2013-05-07 Agfa-Gevaert Nv Security laminates with interlaminated transparent embossed polymer hologram
US8884448B2 (en) 2007-09-28 2014-11-11 Tessera, Inc. Flip chip interconnection with double post
EP2637202A2 (en) 2007-09-28 2013-09-11 Tessera, Inc. Flip chip interconnection with etched posts on a microelectronic element joined to etched posts on a substrate by a fusible metal and corresponding manufacturing method
WO2009043115A1 (en) * 2007-10-04 2009-04-09 Fermiscan Australia Pty Limited Method for identifying biomarkers which are diagnostic for a pathological condition
US8438020B2 (en) 2007-10-12 2013-05-07 Panasonic Corporation Vector quantization apparatus, vector dequantization apparatus, and the methods
US8436334B2 (en) 2007-10-12 2013-05-07 Agency For Science, Technology And Research Fabrication of phosphor free red and white nitride-based LEDs
US8434893B2 (en) 2007-10-17 2013-05-07 Lsi Industries, Inc. Luminaire and methods of use
US8435742B2 (en) 2007-11-01 2013-05-07 Yamaguchi University Method and kit for detection/quantification of target RNA
US8435701B2 (en) * 2007-11-27 2013-05-07 Southbourne Investments Ltd. Holographic recording medium
US8435319B2 (en) 2007-12-07 2013-05-07 Cedric Dackam Filter unit for the filtration of gaseous fluids, in particular air filter in internal combustion engines
US8434344B2 (en) * 2007-12-12 2013-05-07 Service Solutions U.S. Llc Verification of scale calibration method and apparatus
US8435119B2 (en) 2007-12-26 2013-05-07 Scientific Games Holdings Limited User-controlled sweepstakes entries
US8436156B2 (en) 2008-01-04 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
US8436185B2 (en) 2008-01-08 2013-05-07 Merck Sharp & Dohme Corp. Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
US8437997B2 (en) 2008-01-22 2013-05-07 Exxonmobil Upstream Research Company Dynamic connectivity analysis
US8436762B2 (en) 2008-01-31 2013-05-07 Bae Systems Information And Electronic Systems Integration Inc. Determining at least one coordinate of an object using intersecting surfaces
US8436171B2 (en) 2008-02-01 2013-05-07 Akinion Pharmaceuticals Ab Amino substituted pyrazines as inhibitors or protein kinases
US8437963B2 (en) 2008-02-08 2013-05-07 Annica Önell Method, computer program product and system for enabling clinical decision support
US8434703B2 (en) 2008-02-15 2013-05-07 E2V Technologies (Uk) Limited Apparatus and method for comminution of mineral ore
US8435721B2 (en) 2008-02-21 2013-05-07 Nissan Chemical Industries, Ltd. Resist underlayer film forming composition and forming method of resist pattern using the same
US8437069B2 (en) 2008-03-11 2013-05-07 Sipix Imaging, Inc. Luminance enhancement structure for reflective display devices
US8434719B2 (en) 2008-03-13 2013-05-07 Patria Acostructures Oy Leading edge element of aircraft, method for manufacturing one, wing and stabilizer
US8437067B2 (en) 2008-03-18 2013-05-07 Konica Minolta Holdings, Inc. Electrochemical display element
US8437858B2 (en) 2008-03-18 2013-05-07 Imi Intelligent Medical Implants, Ag Visual prosthesis system for displaying video image and text data
US8436157B2 (en) 2008-03-26 2013-05-07 Tate & Lyle Technology Limited Method for the production of sucralose
US8436005B2 (en) 2008-04-03 2013-05-07 Abbott Laboratories Macrocyclic pyrimidine derivatives
US8436078B2 (en) * 2008-04-28 2013-05-07 Kuraray Noritake Dental Inc. Dental composition and composite resin
US8437418B2 (en) 2008-04-30 2013-05-07 Huawei Technologies Co., Ltd. Method and apparatus for detecting signals of multi-input multi-output system
US8436510B2 (en) * 2008-04-30 2013-05-07 Murata Manufacturing Co., Ltd. Boundary acoustic wave device
US8435555B2 (en) 2008-05-01 2013-05-07 Eminate Limited Salt product
EP2617794A2 (en) 2008-05-07 2013-07-24 E. I. du Pont de Nemours and Company Compositions comprising 2,3,3,3- tetrafluoropropene
US8435771B2 (en) 2008-05-07 2013-05-07 Novozymes A/S Fermentation of a lignocellulose-containing material
WO2009135902A2 (en) 2008-05-07 2009-11-12 Vestas Wind Systems A/S A sectional blade
US8435992B2 (en) 2008-05-16 2013-05-07 Pharma Mar S.A. Multiple myeloma treatments
US8435313B2 (en) 2008-05-19 2013-05-07 Furanix Technologies, B.V. Fuel composition
US8436182B2 (en) 2008-05-23 2013-05-07 Zaklady Farmaceutyczne Polpharma Sa Process for preparation of solifenacin and/or the pharmaceutically acceptable salts thereof of high pharmaceutical purity
US8437570B2 (en) 2008-05-23 2013-05-07 Microsoft Corporation Geodesic image and video processing
US8434913B2 (en) 2008-05-30 2013-05-07 Koninklijke Philips Electronics N.V. Round illumination device
US8434605B2 (en) 2008-06-06 2013-05-07 Nsk-Warner K.K. One-way clutch of roller type for starter of motor bike
US8436158B2 (en) 2008-06-18 2013-05-07 Pfizer Inc. Antibodies to IL-6 and their uses
US8435749B2 (en) 2008-06-30 2013-05-07 Oncotherapy Science, Inc. Anti-CDH3 antibodies labeled with radioisotope label and uses thereof
US8436537B2 (en) 2008-07-07 2013-05-07 Samsung Sdi Co., Ltd. Substrate structure for plasma display panel, method of manufacturing the substrate structure, and plasma display panel including the substrate structure
US8435513B2 (en) 2008-07-08 2013-05-07 Oncomed Pharmaceuticals, Inc. NOTCH1 receptor antibodies and methods of treatment
US8436011B2 (en) 2008-07-08 2013-05-07 Sanofi Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
US8434323B2 (en) 2008-07-14 2013-05-07 Johnson Controls Technology Company Motor cooling applications
US8435524B2 (en) 2008-07-16 2013-05-07 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8436134B2 (en) 2008-07-18 2013-05-07 University Of Chicago Semiconducting polymers
US8436012B2 (en) 2008-08-05 2013-05-07 Daiichi Sankyo Company, Limited Imidazopyridin-2-one derivatives
US8437228B2 (en) 2008-08-06 2013-05-07 Hitachi, Ltd. Thermally-assisted magnetic recording head
US8435986B2 (en) 2008-08-14 2013-05-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Bicyclic traizole derivatives for treating of tumors
US8434190B2 (en) 2008-09-01 2013-05-07 Braun Gmbh Toothbrush and method of manufacturing it
US8437857B2 (en) 2008-09-04 2013-05-07 Boston Scientific Neuromodulation Corporation Multiple tunable central cathodes on a paddle for increased medial-lateral and rostral-caudal flexibility via current steering
US8434372B2 (en) 2008-09-12 2013-05-07 Fras Technology As Fluid analysis system and method for operation of an analysis system
US8436015B2 (en) 2008-09-15 2013-05-07 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US8436090B2 (en) 2008-09-16 2013-05-07 Nippon Shokubai Co., Ltd. Production method and method for enhancing liquid permeability of water-absorbing resin
US8435968B2 (en) 2008-09-19 2013-05-07 Pimco 2664 Limited Aryl-phenyl-sulfonamido-cycloalkyl compounds and their use
US8435751B2 (en) 2008-09-25 2013-05-07 Gambro Lundia Ab Membrane for cell expansion
US8437394B2 (en) 2008-09-25 2013-05-07 Mediatek Inc. Adaptive filter
US8438616B2 (en) 2008-09-28 2013-05-07 Huawei Technologies Co., Ltd. Method for terminal configuration and management and terminal device
US8436312B2 (en) * 2008-10-08 2013-05-07 National Institute Of Radiological Sciences DOI type radiation detector
US8436213B2 (en) 2008-10-10 2013-05-07 Exxonmobil Chemical Patents Inc. Process for producing phenol and methyl ethyl ketone
US8434659B2 (en) * 2008-10-14 2013-05-07 Hesse & Knipps Gmbh Bonding device, ultrasonic transducer, and bonding method
US8436413B2 (en) 2008-10-15 2013-05-07 Indian Institute Of Technology, Bombay Nonvolatile floating gate analog memory cell
US8436205B2 (en) 2008-10-23 2013-05-07 Actelion Pharmaceuticals Ltd. Tetrahydronaphthalene compounds
US8435325B2 (en) 2008-10-23 2013-05-07 Hitachi, Ltd. Method and device for removing CO2 and H2S
US8436110B2 (en) 2008-10-31 2013-05-07 Dow Global Technologies Llc Olefin metathesis process employing bimetallic ruthenium complex with bridging hydrido ligands
US8437247B2 (en) 2008-10-31 2013-05-07 Htc Corporation Methods of packet element transmission in wireless communications system
US8436875B2 (en) 2008-11-13 2013-05-07 Sharp Kabushiki Kaisha Display device
US8436200B2 (en) 2008-11-18 2013-05-07 Takeda Pharmaceutical Company Limited Process for making (R)-3-(2,3-dihydroxypropyl)-6-fluoro-5-(2-flouro-4- iodophenylamino)-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione and intermediates thereof
US8438479B2 (en) 2008-11-25 2013-05-07 Panasonic Corporation Operation support apparatus and method of the same
US8437114B2 (en) 2008-11-26 2013-05-07 Murata Manufacturing Co., Ltd. ESD Protection Device
US8436459B2 (en) 2008-11-28 2013-05-07 Mitsubishi Electric Corporation Power semiconductor module
US8436137B2 (en) 2008-12-03 2013-05-07 Koji Kawakami Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide
US8436820B2 (en) 2008-12-04 2013-05-07 Electronics And Telecommunications Research Institute Touchpad using resistive electro-conductive fiber and input device having the same
US8436925B2 (en) 2008-12-08 2013-05-07 Sony Corporation Solid-state imaging device, method for processing signal of solid-state imaging device, and imaging apparatus
US8436444B2 (en) * 2008-12-10 2013-05-07 Si-Nano Inc. Thin film photoelectric conversion device and method for manufacturing thin film photoelectric conversion device
US8436862B2 (en) 2008-12-11 2013-05-07 Nvidia Corporation Method and system for enabling managed code-based application program to access graphics processing unit
US8436614B2 (en) 2008-12-17 2013-05-07 Siemens Aktiengesellschaft Local coil arrangement for magnetic resonance applications with activatable marker
US8434581B2 (en) 2008-12-19 2013-05-07 Zf Friedrichshafen Ag Suspension device having anti-roll compensation
US8436008B2 (en) 2008-12-22 2013-05-07 Incyte Corporation Substituted heterocyclic compounds
US8436270B2 (en) 2008-12-22 2013-05-07 Hypertherm, Inc. Method and apparatus for cutting high quality internal features and contours
US8435917B2 (en) 2008-12-23 2013-05-07 Sued-Chemie Catalysts Italia S.R.L. Ammonia oxidation catalysts
US8436054B2 (en) 2008-12-23 2013-05-07 E I Du Pont De Nemours And Company Fluorinated ionomer produced by aqueous polymerization using dispersed particulate of fluorinated ionomer produced in situ
US8436053B2 (en) 2008-12-23 2013-05-07 E.I. Du Pont De Nemours And Company Fluorinated ionomer produced by aqueous polymerization using dispersed particulate of fluorinated ionomer
US8438452B2 (en) 2008-12-29 2013-05-07 Intel Corporation Poison bit error checking code scheme
US8435355B2 (en) 2008-12-29 2013-05-07 Weyerhaeuser Nr Company Fractionation of lignocellulosic material using ionic liquids
US8435648B2 (en) * 2008-12-30 2013-05-07 Cheil Industries, Inc. Pyridinylene ring compound for organic optoelectronic device, organic light emitting diode including the same and display including the organic light emitting diode
US8436342B2 (en) 2009-01-12 2013-05-07 Samsung Display Co., Ltd. Organic light emitting display device and method of manufacturing the same
US8436092B2 (en) 2009-01-16 2013-05-07 Tsinghua University Giant magnetoresistance composite material containing carbon nanotubes
US8436791B2 (en) * 2009-01-26 2013-05-07 Seiko Epson Corporation Light-emitting device and mobility compensating method for driving the same, and electronic device
US8435768B2 (en) 2009-01-30 2013-05-07 Ajinomoto Co., Inc. Method for producing succinic acid using a yeast belonging to the genus Yarrowia
US8435995B2 (en) 2009-02-05 2013-05-07 Takeda Pharmaceutical Company Limited Pyridazinone compounds
US8435064B2 (en) 2009-02-12 2013-05-07 Fronius International Gmbh Mounting for a DC-AC converter and method for fitting a DC-AC converter
US8436918B2 (en) 2009-02-27 2013-05-07 Deluxe Laboratories, Inc. Systems, apparatus and methods for subtitling for stereoscopic content
US8436488B2 (en) * 2009-03-03 2013-05-07 Bluewater Energy Services B.V. Semi-direct variable speed drive with N+1 power availability
US8437806B2 (en) 2009-03-03 2013-05-07 Lg Electronics Inc. Mobile terminal and method for displaying data in mobile terminal
US8435766B2 (en) 2009-03-19 2013-05-07 N.V. Desmet Ballestra Engineering S.A. Enzymatic oil recuperation process
US8436754B2 (en) 2009-03-27 2013-05-07 Huawei Technologies Co., Ltd. Encoding and decoding method and device
US8436069B2 (en) 2009-03-30 2013-05-07 Fujifilm Corporation Ink composition
EP2623101A1 (en) 2009-04-02 2013-08-07 Merck Patent GmbH Piperidine and piperazine derivatives as autotaxin inhibitors
EP2623491A2 (en) 2009-04-02 2013-08-07 Merck Patent GmbH Piperidine and piperazine derivatives as autotaxin inhibitors
EP2626072A1 (en) 2009-04-02 2013-08-14 Merck Patent GmbH Piperidine and piperazine derivatives as autotaxin inhibitors
US8435272B2 (en) 2009-04-09 2013-05-07 Arthrex, Inc. Clavicle nail with locking end cap
US8435056B2 (en) 2009-04-16 2013-05-07 Enphase Energy, Inc. Apparatus for coupling power generated by a photovoltaic module to an output
US8434781B2 (en) 2009-04-16 2013-05-07 Doona Holdings Ltd Baby safety car seat convertible into a rollable baby seat
US8434422B2 (en) 2009-04-20 2013-05-07 Dow Global Technologies Llc Coating apparatus and method
US8436036B2 (en) 2009-04-24 2013-05-07 Janssen R&D Ireland Diaryl ethers
US8437798B2 (en) 2009-04-27 2013-05-07 Motorola Mobility Llc Uplink scheduling support in multi-carrier wireless communication systems
US8438210B2 (en) 2009-05-04 2013-05-07 Comcast Cable Communications, Llc Sharing media content based on a media server
US8435523B2 (en) 2009-05-04 2013-05-07 Abbott Research B.V. Antibodies against nerve growth factor (NGF) with enhanced in vivo stability
US8435914B2 (en) 2009-05-14 2013-05-07 Univation Technologies, Llc Mixed metal catalyst systems having a tailored hydrogen response
US8437083B2 (en) 2009-05-21 2013-05-07 Canon Kabushiki Kaisha Optical element, optical system including the optical element, and optical apparatus including the optical system
US8437970B2 (en) 2009-06-05 2013-05-07 Apple Inc. Restoring and storing magnetometer calibration data
US8434488B2 (en) 2009-06-08 2013-05-07 Covidien Lp Endotracheal tube with dedicated evacuation port
EP2440937A1 (en) * 2009-06-12 2012-04-18 SBC Research Pty Ltd A diagnostic method
WO2011000020A1 (en) * 2009-06-12 2011-01-06 Sbc Research Pty Ltd Enhanced method of detection
EP2440937A4 (en) * 2009-06-12 2013-05-29 Sbc Res Pty Ltd A diagnostic method
US8437597B2 (en) 2009-06-19 2013-05-07 Corning Cable Systems Llc Mounting of fiber optic cable assemblies within fiber optic shelf assemblies
US8437332B2 (en) 2009-06-22 2013-05-07 Qualcomm Incorporated Low complexity unified control channel processing
US8435961B2 (en) 2009-06-26 2013-05-07 Massachusetts Institute Of Technology Methods and compositions for increasing the activity of inhibitory RNA
US8437827B2 (en) 2009-06-30 2013-05-07 Abbott Diabetes Care Inc. Extruded analyte sensors and methods of using same
US8437278B2 (en) 2009-07-02 2013-05-07 Seiko Epson Corporation Service providing apparatus for digital processing service, wireless communication system, and wireless communication method
US8436102B2 (en) 2009-07-06 2013-05-07 Denki Kagaku Kogyo Kabushiki Kaisha Polychloroprene latex composition, process for production of same, and products of forming thereof
US8435454B2 (en) 2009-07-09 2013-05-07 Siemens Medical Solutions Usa, Inc. Modular system for radiosynthesis with multi-run capabilities and reduced risk of radiation exposure
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
US8434647B2 (en) 2009-08-08 2013-05-07 Riad Aamar Device for measuring and dispensing a prescribed amount of liquid
US8435228B2 (en) 2009-08-12 2013-05-07 Medrad, Inc. Interventional catheter assemblies incorporating guide wire brake and management systems
US8438600B2 (en) 2009-08-20 2013-05-07 Lg Electronics Inc. Method of processing EPG metadata in network device and network device for controlling the same
US8434877B2 (en) 2009-08-20 2013-05-07 Canon Kabushiki Kaisha Illumination optical system and projection display apparatus
US8436172B2 (en) 2009-08-31 2013-05-07 Udc Ireland Limited Material selecting method upon purifying iridium complex by sublimation
US8434718B2 (en) 2009-09-02 2013-05-07 Eurocopter Reusable rotorcraft bumper, and a rotorcraft having such a bumper
US8435976B2 (en) 2009-09-08 2013-05-07 F. Hoffmann-La Roche 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
US8437951B2 (en) 2009-09-14 2013-05-07 Research In Motion Limited Methods, device and systems for determining route metrics using stored route information
US8434308B2 (en) 2009-09-15 2013-05-07 General Electric Company Heat pipes for transferring heat to an organic rankine cycle evaporator
US8436295B2 (en) 2009-09-15 2013-05-07 Canon Anelva Corporation Device for measuring mean free path, vacuum gauge, and method for measuring mean free path
US8436944B2 (en) 2009-10-01 2013-05-07 Panasonic Corporation Wireless communications system, adaptor apparatus for video apparatus, video apparatus and control method for wireless communications system
US8436024B2 (en) 2009-10-02 2013-05-07 Astrazeneca Ab 2-pyridone compounds
US8438021B2 (en) 2009-10-15 2013-05-07 Huawei Technologies Co., Ltd. Signal classifying method and apparatus
US8436002B2 (en) 2009-10-23 2013-05-07 Eli Lilly And Company AKT inhibitors
US8436698B2 (en) 2009-11-02 2013-05-07 Harris Corporation MEMS-based tunable filter
US8435246B2 (en) 2009-11-02 2013-05-07 Synvasive Technology, Inc. Knee arthroplasty apparatus and method
US8435341B2 (en) 2009-11-03 2013-05-07 Agfa-Gevaert N.V. Preparing and dispersing surface-modified colour pigments
US8437308B2 (en) 2009-11-05 2013-05-07 Telefonaktiebolaget L M Ericsson (Publ) Handover measurements in a mobile communication system
US8435415B2 (en) 2009-11-24 2013-05-07 The United States of America, as represented by the Secretary of Commerce, The National Institute of Standards and Technology Nanofabrication process and nanodevice
US8436833B2 (en) 2009-11-25 2013-05-07 Corning Incorporated Methods and apparatus for sensing touch events on a display
US8437962B2 (en) 2009-11-25 2013-05-07 Halliburton Energy Services, Inc. Generating probabilistic information on subterranean fractures
US8436491B2 (en) 2009-11-30 2013-05-07 Broadcom Corporation Low pin count wireless power IC
WO2011067465A1 (en) 2009-12-04 2011-06-09 Kristiina Rajala Formulations and methods for culturing stem cells
US8434383B2 (en) 2009-12-04 2013-05-07 Hyundai Motor Company Transmission shifting apparatus for vehicle
US8437773B2 (en) 2009-12-09 2013-05-07 Qualcomm Incorporated Hierarchical information dissemination for location based systems
US8434914B2 (en) 2009-12-11 2013-05-07 Osram Sylvania Inc. Lens generating a batwing-shaped beam distribution, and method therefor
US8435342B2 (en) 2009-12-15 2013-05-07 Shell Oil Company Concrete composition
US8437183B2 (en) 2009-12-16 2013-05-07 Sandisk Il Ltd. Auxiliary parity bits for data written in multi-level cells
US8435209B2 (en) 2009-12-30 2013-05-07 Medtronic Minimed, Inc. Connection and alignment detection systems and methods
US8438231B2 (en) 2010-01-08 2013-05-07 Alcatel Lucent Telecommunication messaging through a social networking service
US8435828B2 (en) 2010-01-13 2013-05-07 Renesas Electronics Corporation Method of manufacturing semiconductor device
US8435792B2 (en) 2010-01-14 2013-05-07 Baxter International Inc. Methods and compositions for treating bleeding disorders
US8437794B2 (en) 2010-01-28 2013-05-07 Alcatel Lucent Methods of determining uplink target signal-to-interfence-and-noise ratios and systems thereof
US8436383B2 (en) * 2010-02-17 2013-05-07 Lg Innotek Co., Ltd. Light emitting device, light emitting device package, and lighting system
US8437882B2 (en) * 2010-02-17 2013-05-07 Inscope Energy, Llc Managing power utilized within a local power network
US8434906B2 (en) 2010-02-23 2013-05-07 General Electric Company Lighting system with thermal management system
WO2011104644A1 (en) 2010-02-24 2011-09-01 Koninklijke Philips Electronics N.V. Hid lighting system
WO2011104713A1 (en) 2010-02-25 2011-09-01 Nova Measuring Instruments Ltd. Method and system for measurng in patterned structures
US8434286B2 (en) 2010-03-03 2013-05-07 Yuyama Manufacturing Co., Ltd. Medicament dispensing machine
US8437594B2 (en) 2010-03-16 2013-05-07 Furukawa Electric Co., Ltd. Holey fiber
US8437173B2 (en) 2010-03-19 2013-05-07 Panasonic Corporation Nonvolatile memory element, manufacturing method thereof, design support method therefor, and nonvolatile memory device
US8434889B2 (en) 2010-03-19 2013-05-07 GE Lighting Solutions, LLC Lighted display case having reduced glare
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
WO2011116811A1 (en) 2010-03-24 2011-09-29 Telefonaktiebolaget Lm Ericsson (Publ) A node with an improved back up protocol
US8435402B2 (en) * 2010-03-29 2013-05-07 Marathon Canadian Oil Sands Holding Limited Nozzle reactor and method of use
US8436060B2 (en) 2010-03-30 2013-05-07 Samsung Electronics Co., Ltd. Organic aerogel and composition for the organic aerogel
US8436065B2 (en) 2010-04-01 2013-05-07 Samsung Electronics Co., Ltd. Aerogel, and composition and method for manufacture of the aerogel
US8436512B2 (en) 2010-04-06 2013-05-07 Senseor Method of rapidly interrogating elastic wave sensors
US8436001B2 (en) 2010-04-07 2013-05-07 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
US8435778B2 (en) 2010-05-13 2013-05-07 Suntory Holdings Limited Gene encoding lignan methyltransferase and use thereof
US8436755B2 (en) 2010-05-21 2013-05-07 Research In Motion Limited Methods and devices for reducing sources in binary entropy coding and decoding
US8435486B2 (en) * 2010-05-24 2013-05-07 Toyota Jidosha Kabushiki Kaisha Redox material for thermochemical water splitting, and method for producing hydrogen
US8436218B2 (en) 2010-05-27 2013-05-07 Honeywell International Inc. Azeotrope-like composition of hexafluoropropane, hexafluoropropene and hydrogen fluoride
US8435409B2 (en) 2010-05-28 2013-05-07 Ecolab Usa Inc. Activated sludge process in wastewater treatment
US8434910B2 (en) 2010-06-01 2013-05-07 Lg Innotek Co., Ltd. Light emitting device package and lighting system
US8437527B2 (en) 2010-06-16 2013-05-07 Hitachi Aloka Medical, Ltd. Ultrasound diagnostic apparatus
US9030001B2 (en) 2010-07-27 2015-05-12 Tessera, Inc. Microelectronic packages with nanoparticle joining
US9397063B2 (en) 2010-07-27 2016-07-19 Tessera, Inc. Microelectronic packages with nanoparticle joining
US8434184B2 (en) 2010-08-13 2013-05-07 Braun Gmbh Fracture resistant brush head
US8434183B2 (en) 2010-08-13 2013-05-07 Braun Gmbh Brush section for an electric toothbrush
US8434776B2 (en) 2010-08-16 2013-05-07 Andy WUTHRICH Bicycle frame with rear suspension system
US8438272B2 (en) 2010-08-31 2013-05-07 Sap Ag Methods and systems for managing quality of services for network participants in a networked business process
US8434242B2 (en) 2010-09-16 2013-05-07 Velico Medical, Inc. Spray dried human plasma
WO2012043067A1 (en) 2010-09-27 2012-04-05 日本電気株式会社 Vehicle-mounted device and congestion control method
WO2012043801A1 (en) 2010-09-30 2012-04-05 積水メディカル株式会社 Patch
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US8436114B2 (en) 2010-10-21 2013-05-07 Exxonmobil Chemical Patents Inc. Polyethylene and process for production thereof
US8434460B2 (en) 2010-10-29 2013-05-07 Ford Global Technologies, Llc Integrally molded carbon canister
WO2012070099A1 (en) 2010-11-22 2012-05-31 東芝三菱電機産業システム株式会社 Rolling mill control device
US8435993B2 (en) 2010-12-07 2013-05-07 Philadelphia Health And Education Corporation Methods of inhibiting metastasis from cancer
US9496236B2 (en) 2010-12-10 2016-11-15 Tessera, Inc. Interconnect structure
US8438044B2 (en) 2011-01-18 2013-05-07 Audiahealth, Llc Systems and methods combining print and audio technologies to deliver and personalize health information
US8437177B2 (en) 2011-01-20 2013-05-07 Panasonic Corporation Nonvolatile latch circuit and nonvolatile flip-flop circuit
US8434524B2 (en) 2011-01-31 2013-05-07 Vanderbilt University Elastic hydraulic accumulator/reservoir system
US8435275B2 (en) 2011-03-30 2013-05-07 Valkee Oy Portable ear light device
US8437079B2 (en) 2011-05-06 2013-05-07 Leapers, Inc. Apparatus including a reticle, assembly and method for operating the same
US8435545B2 (en) * 2011-09-01 2013-05-07 Qualicaps, Inc. Capsule having broad color spectrum
WO2013124832A2 (en) 2012-02-24 2013-08-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
WO2013128380A1 (en) 2012-02-28 2013-09-06 Koninklijke Philips N.V. Device for light based skin treatment
WO2013128369A1 (en) 2012-02-28 2013-09-06 Koninklijke Philips N.V. Aed with compression sensor
WO2013132448A1 (en) 2012-03-07 2013-09-12 Kba-Notasys Sa Method of checking producibility of a composite security design of a security document on a line of production equipment and digital computer environment for implementing the same
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
EP2796145A1 (en) 2013-04-22 2014-10-29 CSL Behring GmbH Complex
EP2796818A1 (en) 2013-04-22 2014-10-29 Shell Internationale Research Maatschappij B.V. Method and apparatus for producing a liquefied hydrocarbon stream
US9633971B2 (en) 2015-07-10 2017-04-25 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles
US9818713B2 (en) 2015-07-10 2017-11-14 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles
US10535626B2 (en) 2015-07-10 2020-01-14 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles
US10886250B2 (en) 2015-07-10 2021-01-05 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles
US10892246B2 (en) 2015-07-10 2021-01-12 Invensas Corporation Structures and methods for low temperature bonding using nanoparticles
US11710718B2 (en) 2015-07-10 2023-07-25 Adeia Semiconductor Technologies Llc Structures and methods for low temperature bonding using nanoparticles
WO2019186577A1 (en) 2018-03-27 2019-10-03 Council Of Scientific And Industrial Research A non-invasive and remote method to screen cancer
US11561187B2 (en) 2018-03-27 2023-01-24 Council Of Scientific And Industrial Research Non-invasive and remote method to screen cancer

Also Published As

Publication number Publication date
TW200801513A (en) 2008-01-01
EP2032031B1 (en) 2011-08-17
AU2007264394A1 (en) 2008-01-03
ATE520345T1 (en) 2011-09-15
CN101478916A (en) 2009-07-08
EP2032031A1 (en) 2009-03-11
KR20090035556A (en) 2009-04-09
KR101087576B1 (en) 2011-11-29
ES2371368T3 (en) 2011-12-30
JP2009541747A (en) 2009-11-26
EP2032031A4 (en) 2010-03-24
CA2652955A1 (en) 2008-01-03
AU2007264394B2 (en) 2012-08-16
US20090325303A1 (en) 2009-12-31
AR061732A1 (en) 2008-09-17
BRPI0713885A2 (en) 2012-11-06

Similar Documents

Publication Publication Date Title
AU2007264394B2 (en) Improved process
Elkins Rapid presumptive “fingerprinting” of body fluids and materials by ATR FT‐IR spectroscopy
CN105096225B (en) The analysis system of aided disease diagnosis and treatment, device and method
Giori et al. High-resolution gel electrophoresis and sodium dodecyl sulphate–agarose gel electrophoresis on urine samples for qualitative analysis of proteinuria in dogs
Klyuchko Biotechnical information systems for monitoring of chemicals in environment: biophysical approach
Ghafar et al. Comparative studies on faecal egg counting techniques used for the detection of gastrointestinal parasites of equines: A systematic review
JP3569231B2 (en) Method for diagnosing TSE-induced tissue changes using infrared spectroscopy
Clark et al. Lipid normalization and stable isotope discrimination in Pacific walrus tissues
Gao et al. Sensitivity of sniffer dogs for a diagnosis of Parkinson's Disease: a diagnostic accuracy study
Mahmoud et al. Two-step machine learning method for the rapid analysis of microvascular flow in intravital video microscopy
Tsongalis et al. Applications of forensic identity testing in the clinical laboratory
Baptista et al. Comparative study of inorganic elements determination in whole blood from Crioula breed horse by EDXRF and NAA analytical techniques
Giuseppe et al. Preliminary study for the application of Raman spectroscopy for the identification of Leishmania infected dogs
Hawkins et al. The Cu, Mn and Zn concentration of sheep wool: Influence of washing procedures, age and colour of matrix
JP2015505359A5 (en)
Dove et al. Spatio‐temporal variation in serum chemistry of the lobster, Homarus americanus Milne‐Edwards
US20050079099A1 (en) Generation of biochemical images and methods of use
AU755041B2 (en) Automated diagnostic system implementing immunoassays and clinical chemistry assays according to a reflex algorithm
Ansari-Lari et al. Comparative study of plasma proteins including haptoglobin and serum amyloid A in different types of traumatic reticuloperitonitis in cattle
Cheleuitte-Nieves Enrichment and outcomes in female lab mice
Miller et al. Why do captive tufted capuchins (Cebus apella) urine wash?
Cunningham et al. Tox/Path team takes on differential gene expression.
US20050112695A1 (en) Method of detecting bovine spongiform encephalopathy
Morandi et al. Endoparasites in dogs diagnosed at the Veterinary Teaching Hospital (VTH)-University of Bologna, combined with clinicopathological results. A long-term retrospective secondary data study
Bosco et al. Comparison of Mini-FLOTAC, Flukefinder

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780024380.0

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07719118

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2652955

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007264394

Country of ref document: AU

Ref document number: 573761

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 5170/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007719118

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009516820

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007264394

Country of ref document: AU

Date of ref document: 20070627

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1020097001887

Country of ref document: KR

Ref document number: KR

WWE Wipo information: entry into national phase

Ref document number: 12306134

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0713885

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081229